

Lyme disease: diagnosis and management

[L] Evidence review for the management of persistent symptoms related to Lyme disease

NICE guideline

Evidence review

September 2017

Draft for Consultation

*This evidence review was developed by
the National Guideline Centre*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2017. All rights reserved. Subject to Notice of rights.

ISBN:

Contents

1	Management (persistent symptoms)	6
1.1	Review question: What is the most clinically and cost-effective treatment for seropositive people, who have non-specific symptoms that may be related to Lyme disease?	6
1.2	Introduction	6
1.3	PICO table.....	6
1.4	Clinical evidence	7
1.4.1	Included studies	7
1.4.2	Excluded studies.....	8
1.4.3	Summary of clinical studies included in the evidence review.....	8
1.4.4	Quality assessment of clinical studies included in the evidence review	10
1.5	Economic evidence	14
1.5.1	Included studies	14
1.5.2	Excluded studies.....	14
1.5.3	Unit costs	15
1.6	Resource impact	18
1.7	Evidence statements	18
1.7.1	Clinical evidence statements.....	18
1.7.2	Health economic evidence statements.....	18
1.8	Recommendations	18
1.8.1	Research recommendations	19
1.9	Rationale and impact.....	19
1.9.1	Why the committee made the recommendations.....	19
1.9.2	Impact of the recommendations on practice.....	20
1.10	The committee's discussion of the evidence.....	20
1.10.1	Interpreting the evidence.....	20
1.10.2	Cost effectiveness and resource use	21
1.10.3	Other factors the committee took into account	21
1.11	Recommendations	23
1.12	Rationale and impact.....	23
1.12.1	Why the committee made the recommendations.....	23
1.12.2	Impact of the recommendations on practice	23
1.13	The committee's discussion of the evidence.....	24
1.13.1	Interpreting the evidence.....	24
1.13.2	Cost effectiveness and resource use	24
1.13.3	Other factors the committee took into account	24
	References	25
	Appendices	38

Appendix A: Review protocols	38
Appendix B: Literature search strategies	43
B.1 Clinical search literature search strategy	43
B.2 Health Economics literature search strategy	45
Appendix C: Clinical evidence selection	51
Appendix D: Clinical evidence tables	52
Appendix E: Forest plots.....	59
E.1.1 Persistent Lyme disease symptoms.....	59
E.2.1 Persistent Lyme disease symptoms.....	60
E.3.1 Persistent Lyme disease symptoms.....	61
E.4.1 Persistent Lyme disease symptoms.....	61
E.5.1 Persistent Lyme disease symptoms.....	62
Appendix F: GRADE tables	63
Appendix G: Health economic evidence selection.....	68
Appendix H: Health economic evidence tables	69
Appendix I: Excluded studies.....	70
I.1 Excluded clinical studies.....	70
I.2 Excluded health economic studies.....	74

1 Management (persistent symptoms)

1.1 Review question: What is the most clinically and cost-effective treatment for seropositive people, who have non-specific symptoms that may be related to Lyme disease?

1.2 Introduction

If Lyme disease is treated early, most people recover completely, but studies show that some people have persistent symptoms following antibiotic treatment. It is not known whether these symptoms are due to persisting infection, tissue damage, autoimmune reaction or some other process. There is currently no test that helps determine this. It is important to assess whether repeat or longer courses of antibiotics might help.

A number of treated people have a slow recovery and may need support and access to social services. It is important that clinical practitioners consider these when managing people with long-term symptoms related to Lyme disease.

This section includes an evidence report and committee discussion on antibiotic management of persisting symptoms as well as a separate section with recommendations and committee discussion about the importance of provision of longer-term support.

1.3 PICO table

For full details, see the review protocol in appendix A.

Table 1: PICO characteristics of review question

Population	People with Lyme disease determined by a diagnostic tests or clinical diagnosis who have non-specific symptoms that may be related to Lyme disease. This includes symptoms such as: <ul style="list-style-type: none">• disturbed cognitive function, for example, memory loss• dizziness• fatigue• fever and sweats• headache• lymphadenopathy• myalgia and muscle stiffness• neck pain or stiffness• paraesthesia• photophobia
Interventions	Antimicrobials, including but not limited to: <ul style="list-style-type: none">• Penicillins<ul style="list-style-type: none">○ Amoxicillin (oral, IV)○ Ampicillin (oral, IV)○ Benzylpenicillin sodium / Penicillin G (IV)<ul style="list-style-type: none">- Including Augmentin (Amoxicillin and clavulanic acid; oral, IV)○ Phenoxyethylpenicillin / Penicillin V (oral)• Tetracyclines<ul style="list-style-type: none">○ Doxycycline (oral)○ Minocycline (oral)• Cephalosporins

	<ul style="list-style-type: none"> ○ Cefotaxime (IV) ○ Ceftriaxone (IV) ○ Cefuroxime axetil (oral) ● Macrolides <ul style="list-style-type: none"> ○ Azithromycin (oral) ○ Clarithromycin (oral, IV) ● Fluoroquinolones <ul style="list-style-type: none"> ○ Ciprofloxacin (oral, IV) ○ Levofloxacin (oral, IV) ○ Moxifloxacin (oral, IV) ○ Nalidixic acid (oral) ○ Norfloxacin (oral) ○ Ofloxacin (oral, IV) ● Rifampicin (oral, IV)
Comparisons	<ul style="list-style-type: none"> ● Antimicrobial agents compared with each other <ul style="list-style-type: none"> ○ If data are available, consider: <ul style="list-style-type: none"> - Type of antimicrobial agent (within class or between class) - Route of administration - Duration of treatment: 1 month versus longer ● Monotherapy versus polytherapy (any combination) ● Antimicrobial agents compared to no treatment / placebo
Outcomes	<p>Critical:</p> <ol style="list-style-type: none"> 1. Quality of life (any validated measure) 2. Cure (resolution of symptoms) 3. Reduction of clinical symptoms 4. Symptom relapse <p>Important:</p> <ol style="list-style-type: none"> 5. Adverse events
Study design	<ul style="list-style-type: none"> ● Randomised control studies (RCT) ● Cohort studies (if no RCT evidence is found)

1 1.4 Clinical evidence

2 1.4.1 Included studies

3 The evidence reviews conducted for antibiotic management of Lyme disease did not pre-
4 specify for how long a person with symptoms related to Lyme disease had those symptoms
5 but was organised by symptom or symptom complex. The review question on the
6 management of non-specific symptoms related to Lyme disease did not identify any studies
7 in people with non-specific symptoms in the early stages of Lyme disease. Three studies
8 identified^{15,80,85} were in adults where a significant proportion of the people in these studies
9 had received antibiotic treatment prior to enrolment. The committee agreed that these
10 studies would inform recommendations about treating people with symptoms persisting after
11 treatment.

12 All participants in the PLEASE trial¹⁵ received 2 grams intravenous ceftriaxone for 14 days
13 prior to the study interventions. One treatment arm in this trial also used an indirect
14 intervention as people received hydroxychloroquine in addition to clarithromycin.

15 The included studies are summarised in Table 2 below. Evidence from these studies is
16 summarised in the clinical evidence summary below (Table 3).

17 See also the study selection flow chart in appendix C, study evidence tables in appendix D,
18 forest plots in appendix E and GRADE tables in appendix F.

1 **1.4.2 Excluded studies**

2 See the excluded studies list in appendix I.

3 **1.4.3 Summary of clinical studies included in the evidence review**

4 **Table 2: Summary of studies included in the evidence review**

Study	Intervention and comparison	Population	Outcomes	Comments
Berende 2016 (PLEASE trial) ¹⁵	<p>Doxycycline (n=86): 100 mg oral twice daily. Duration 12 weeks. Concurrent medication/care: Placebo combined with study intervention.</p> <p>Clarithromycin (n=96): 500 mg clarithromycin orally twice daily plus 200 mg hydroxychloroquine orally twice daily. Duration 12 weeks. Concurrent medication/care: none</p> <p>Placebo (n=98): Two different placebo capsules orally twice daily. Duration 12 weeks. Concurrent medication/care: none</p>	<p>n=281</p> <p>Diagnosis: persistent symptoms attributed to Lyme disease temporarily related to an EM or an otherwise proven case of symptomatic Lyme disease or accompanied by <i>B burgdorferi</i> IgM or IgG antibodies</p>	<p>Quality of life</p> <p>Adverse events</p>	<p>People in the clarithromycin group also received hydroxychloroquine</p> <p>All people received open-label intravenous ceftriaxone (2,000 mg daily) for 14 days prior to study intervention.</p> <p>Majority of people (87-91%) had received previous antibiotic treatment</p>
Klempner 2001 ⁸⁰	<p>Polytherapy (n=64): 2 g ceftriaxone per day intravenous for 30 days followed by 100 mg doxycycline orally twice per day for 60 days. Duration 90 days. Concurrent medication/care: Not reported</p> <p>Placebo (n=65): Dextrose solution intravenous for 30 days followed by oral capsules for 90 days. Duration 90 days. Concurrent medication/care: Not reported</p>	<p>n=129</p> <p>Diagnosis: history of acute Lyme disease acquired in the US and at least 1 of the following: history of single or multiple EM, early neurologic or cardiac symptoms attributed to Lyme disease, radiculoneuropathy, or Lyme arthritis</p>	<p>Quality of life</p> <p>Adverse events</p>	<p>33% had previously received intravenous antibiotic treatment for mean (\pmSD) 30 \pm 12 days, all other previous treatment consisted of oral antibiotics (mean 3 \pm 1.4 courses in the antibiotic group; 2.7 \pm 1.3 in the placebo group)</p>

Study	Intervention and comparison	Population	Outcomes	Comments
Krupp 2003 ⁸⁵	<p>Ceftriaxone (n=28): 2 g per day, intravenous. Duration 28 days. Concurrent medication/care: Not reported</p> <p>Placebo (n=27): Placebo intravenous. Duration 28 days. Concurrent medication/care: Not reported</p>	<p>n=56</p> <p>Diagnosis: history of physician-documented EM or CDC-defined late manifestation of Lyme disease confirmed by positive ELISA and WB serology, current severe fatigue defined by an elevated score (4 or more) on a modified version of the Fatigue Severity Scale</p>	Reduction of symptoms	Eligibility criteria included completion (6 months before study entry) of standard antibiotic therapy for Lyme disease as defined by at least a 3 week course of oral antibiotic therapy or 3 weeks of IV ceftriaxone

1 See appendix D for full evidence tables.

1 **1.4.4 Quality assessment of clinical studies included in the evidence review**

2 **Table 3: Clinical evidence summary: Ceftriaxone (IV) followed by doxycycline (PO) versus placebo**

Outcomes	Number of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with placebo	Risk difference with ceftriaxone and doxycycline (95% CI)
Improvement in quality of life at 180 days	115 (1 study)	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 1.11 (0.7 to 1.77)	362 per 1,000	40 more per 1,000 (from 109 fewer to 279 more)
Improvement in SF-36 (physical component) at 180 days; 0-100, higher values are beneficial	115 (1 study)	LOW ^{1,2} due to risk of bias, imprecision	RR 1.36 (0.77 to 2.38)	259 per 1,000	93 more per 1,000 (from 59 fewer to 357 more)
Improvement in SF-36 (mental component) at 180 days; 0-100, higher values are beneficial	115 (1 study)	VERY LOW ^{1,2} due to risk of bias, imprecision	RR 0.88 (0.54 to 1.44)	379 per 1,000	46 fewer per 1,000 (from 174 fewer to 167 more)
Adverse events at 90 days	129 (1 study)	LOW ² due to imprecision	RR 1.48 (0.74 to 2.93)	169 per 1,000	81 more per 1,000 (from 44 fewer to 327 more)
¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias ² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs					

Table 4: Clinical evidence summary: Ceftriaxone (IV) versus placebo

Outcomes	Number of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with placebo	Risk difference with ceftriaxone (95% CI)
Improvement in fatigue at 6 months	55 (1 study)	HIGH	RR 3.47 (1.5 to 8.02)	185 per 1,000	457 more per 1,000 (from 93 more to 1,000 more)
FSS-11 score (final values) at 6 months; 0-77, lower values are beneficial	48 (1 study)	LOW ^{1,2} due to risk of bias, imprecision	Not applicable	The mean FSS-11 score in the control group was 5.5	The mean FSS-11 score in the intervention group was 1.1 lower (1.89 to 0.31 lower)
Change in FSS-11 score from baseline at 6 months; 0-77, lower values are beneficial	48 (1 study)	LOW ^{1,2} due to risk of bias, imprecision	Not applicable	The mean change in FSS-11 score from baseline in the control group was -0.5	The mean change in FSS-11 score from baseline in the intervention group was 0.8 lower (1.46 to 0.14 lower)
Improvement in cognitive measure at 6 months	48 (1 study)	LOW ² due to imprecision	RR 0.85 (0.13 to 5.52)	91 per 1,000	14 fewer per 1,000 (from 79 fewer to 411 more)
A-A score (final values) at 6 months; cognitive processing speed measured in milliseconds, lower values are beneficial	48 (1 study)	MODERATE ² due to imprecision	Not applicable	The mean A-A score in the control group was 3.4	The mean A-A score in the intervention group was 0.4 higher (0.38 lower to 1.18 higher)
Change in A-A score from baseline at 6 months; cognitive processing speed measured in milliseconds, lower values are beneficial	47 (1 study)	MODERATE ² due to imprecision	Not applicable	The mean change in A-A score from baseline in the control group was -0.5	The mean change in A-A score from baseline in the intervention group was 0.2 higher (0.32 lower to 0.72 higher)

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

Table 5: Clinical evidence summary: Ceftriaxone (IV) followed by doxycycline (PO) versus ceftriaxone (IV) followed by clarithromycin (PO) plus hydroxychloroquine

Outcomes	Number of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with ceftriaxone plus clarithromycin plus hydroxychloroquine	Risk difference with ceftriaxone plus doxycycline (95% CI)
SF-36 (physical component – final values) at 14 weeks; 15-61 (norm-based T-score), general population score 50 (SD 10), higher values are beneficial	182 (1 study)	LOW ^{1,2} due to indirectness, imprecision	Not applicable	The mean SF-36 (physical component) in the control group was 35.6	The mean SF-36 (physical component) in the intervention group was 0.6 lower (2.62 lower to 1.42 higher)
Adverse events at 14 weeks	182 (1 study)	LOW ^{1,2} due to indirectness, imprecision	RR 1.12 (0.82 to 1.53)	438 per 1,000	53 more per 1,000 (from 79 fewer to 232 more)
Discontinued treatment due to adverse events at 14 weeks	182 (1 study)	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.48 (0.13 to 1.79)	73 per 1,000	38 fewer per 1,000 (from 63 fewer to 58 more)

¹ People in the clarithromycin group also received hydroxychloroquine
² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

Table 6: Clinical evidence summary: Ceftriaxone (IV) followed by doxycycline (PO) versus ceftriaxone (IV)

Outcomes	Number of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with ceftriaxone	Risk difference with ceftriaxone plus doxycycline (95% CI)
SF-36 (physical component – final values) at 14 weeks; 15-61 (norm-based T-score), general population score 50 (SD 10), higher	184 (1 study)	MODERATE ¹ due to imprecision	Not applicable	The mean SF-36 (physical component) in the control group was	The mean SF-36 (physical component) in the intervention group was 0.2 higher (1.82 lower to 2.22 higher)

Outcomes	Number of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with ceftriaxone	Risk difference with ceftriaxone plus doxycycline (95% CI)
values are beneficial				34.8	
Adverse events at 14 weeks	184 (1 study)	MODERATE ¹ due to imprecision	RR 1.41 (0.99 to 1.99)	347 per 1,000	142 more per 1,000 (from 3 fewer to 343 more)
Discontinued treatment due to adverse events at 14 weeks	184 (1 study)	LOW ¹ due to imprecision	RR 0.85 (0.2 to 3.71)	41 per 1,000	6 fewer per 1,000 (from 33 fewer to 111 more)

¹ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

Table 7: Clinical evidence summary: Ceftriaxone (IV) followed by clarithromycin (PO) plus hydroxychloroquine versus ceftriaxone (IV)

Outcomes	Number of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with ceftriaxone	Risk difference with ceftriaxone plus clarithromycin plus hydroxychloroquine (95% CI)
SF-36 (physical component – final values) at 14 weeks; 15-61 (norm-based T-score), general population score 50 (SD 10), higher values are beneficial	194 (1 study)	LOW ^{1,2} due to indirectness, imprecision	Not applicable	The mean SF-36 (physical component) in the control group was 34.8	The mean SF-36 (physical component) in the intervention group was 0.8 higher (1.15 lower to 2.75 higher)
Adverse events at 14 weeks	194 (1 study)	LOW ^{1,2} due to indirectness, imprecision	RR 1.26 (0.89 to 1.8)	347 per 1,000	90 more per 1,000 (from 38 fewer to 278 more)
Discontinued treatment due to adverse events at 14 weeks	194 (1 study)	VERY LOW ^{1,2} due to indirectness, imprecision	RR 1.79 (0.54 to 5.91)	41 per 1,000	32 more per 1,000 (from 19 fewer to 200 more)

¹ People in the clarithromycin group also received hydroxychloroquine
² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

See appendix F for full GRADE tables.

1 **1.5 Economic evidence**

2 **1.5.1 Included studies**

3 No relevant health economic studies were identified.

4 See also the health economic study selection flow chart in appendix G.

5 **1.5.2 Excluded studies**

6 No relevant health economic studies were identified and excluded.

1 **1.5.3 Unit costs**

2 The following unit costs were presented to the committee to aid consideration of cost-effectiveness.

3 **Table 8: UK costs of antimicrobials**

Class	Drug	Age	Preparation	Mg/unit	Cost/unit (£)	Units/day	Course duration (days)	Cost per course (£)
Penicillins	Amoxicillin	7 days-11 months	125 mg/1.25 ml oral suspension paediatric	125	0.20	3	14–28	8.35–16.70
		1-4 years	250 mg/5 ml oral suspension	250	0.06	3	14–28	2.37–4.75
		>5 years	capsules	500	0.06	3	14–28 (g)	2.54–5.08
Penicillins	Phenoxy-methylpenicillin	Adults (a)	tablets	250	0.04	4	10	1.49
Tetracyclines	Doxycycline	>12 years	capsules	100	0.11	2	10–28 (h)	2.18–6.09
Cephalosporins	Cefuroxime axetil	>3 months	tablets	250	1.27	4	14–28 (g)	70.88–141.76
Macrolide	Clarithromycin	>1 month	tablets	500	0.16	2	14–21	4.42–6.63
Macrolide	Azithromycin	<12 years	40 mg/1 ml oral suspension	40	0.27	10 mg/kg	9 (i)	Weight dependent
		Adults	tablets	500	0.42	1	9 (i)	3.75
Cephalosporins	Cefotaxime	Adults (b)	2 g powder for solution for injection vials (IV)	2,000	3.75	3	10	112.50
Cephalosporins	Ceftriaxone	>9 years (c) (d)	2 g powder for solution for injection vials (IV) (e)	2,000	1.03	1	14–21	14.42–21.63
Penicillins	Benzylpenicillin sodium	Adults (f)	600 mg powder for solution for injection vials (IM)	600	2.73	2	3	16.38

4 *Abbreviations: IM: intramuscular; IV: intravenously.*

Sources: Unit costs from NHS Electronic Drug Tariff January 2017,¹²⁰ except cefotaxime from BNF, January 2017²¹ and ceftriaxone from EMIT March 2017;³⁸ dosage from BNF and BNF for Children January 2017,^{21,22} exceptions below:

- (a) Source of dosage from RCT in adults with EM: Steere 1983,¹⁶⁷ dosage for Lyme disease not available from BNF or BNF for children.
- (b) Source of dosage from RCT in adults with neuroborreliosis: Pfister 1989¹³² and Pfister 1991,¹³³ dosage for Lyme disease not available from BNF or BNF for children.^{21,22}
- (c) For disseminated Lyme borreliosis.
- (d) Dose for neonate and child up to 11 years (body weight <50 kg) 50-80 mg/kg once daily for 14-21 days. BNF for children January 2017.²²
- (e) Administration can vary in adults and children >1 month: IV infusion over 30 mins or IV injection over 5 mins or deep muscular injection (doses over 1 g divided between more than 1 site): 2 g per day for 14-21 days BNF January 2017.²¹
- (f) Source of dosage from RCT in adults with Lyme arthritis: Steere 1985:¹⁶⁶ 1.2 million U injected in each buttock weekly intramuscularly. Duration 3 weeks. Dosage for Lyme disease not available from BNF or BNF for children.^{21,22}
- (g) Course duration for early Lyme 14-21 days; 28 days for Lyme arthritis. BNF January 2017.²¹
- (h) Course duration for early Lyme 10-14 days; 28 days for Lyme arthritis. BNF January 2017.²¹
- (i) Course dose and duration for adults: 500 mg once daily for 3 days, for 3 weeks. For children under 12 years: 10 mg/kg once daily for 3 days for 3 weeks. Committee expert opinion.

The cost of intravenous antibiotics will vary depending on where these are administered and by whom. These costs will include some of the following cost components:

- antibiotic
- nursing time (for example, Band 6 nurse, £44 per hour, PSSRU 2016⁴¹)
- clinic space and clerical time (for outpatient administration)
- travel time (for home administration)
- hospital bed (for inpatient administration)
- consumables (for example, cannula, needles, syringes, dressing, IV giving set and glucose or sodium chloride solution).

A large proportion of the total cost of intravenous antibiotics is likely to be the cost of administration rather than the drug itself. As a result, intravenous drugs that have multiple doses administered per day will be more costly than those administered once daily. This was explored in a detailed costing analysis conducted for the NICE CG102 (Meningitis [bacterial] and meningococcal septicaemia in under 16s).¹¹⁷ In this analysis, they found that ceftriaxone was the cheapest antibiotic when compared to cefotaxime and benzylpenicillin. This was due to savings in staff time associated with once daily dosing, which offset the higher cost of the drug itself.

Inpatient administration

Intravenous antibiotics administered in an inpatient setting will incur the cost of an inpatient stay, which is assumed to include intravenous antibiotics treatment as part of the unit cost. The weighted average unit cost of non-elective inpatient stays and day cases for infectious disease in adults and children are summarised estimated in the table below using the NHS reference costs 2015/2016.⁴⁶

Table 9: Unit costs of inpatient administration

Schedule	Currency description	Currency codes	Weighted average unit costs (per day)
Day-case adults	Standard/major/complex infectious diseases with/without single/multiple interventions, with/without CC	WJ01B, WJ01D, WJ01E, WJ02B, WJ02C, WJ02D, WJ02E, WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F, WJ03G	£352
Day-case paediatrics	Paediatric minor/major/intermediate infections with/without CC	PW01A, PW01B, PW01C, PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E, PW17F, PW17G	£448
Non-elective inpatient short-stay adults	Standard/major/complex infectious diseases with/without single/multiple interventions, with/without CC	WJ01A, WJ01B, WJ01C, WJ01D, WJ01E, WJ02A, WJ02B, WJ02C, WJ02D, WJ02E, WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F, WJ03G	£432
Non-elective inpatient short-stay paediatrics	Paediatric minor/major/intermediate infections with/without CC	PW01A, PW01B, PW01C, PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E, PW17F, PW17G	£521
Non-elective inpatient long-stay adults	Standard/major/complex infectious diseases with/without single/multiple interventions, with/without CC	WJ01A, WJ01B, WJ01C, WJ01D, WJ01E, WJ02A, WJ02B, WJ02C, WJ02D, WJ02E, WJ03A, WJ03B, WJ03C, WJ03D, WJ03E, WJ03F, WJ03G	£473
Non-elective inpatient long-stay paediatrics	Paediatric minor/major/intermediate infections with/without CC	PW01A, PW01B, PW01C, PW16A, PW16B, PW16C, PW16D, PW16E, PW17D, PW17E, PW17F, PW17G	£699

Source: NHS reference costs 2015/2016⁴⁶

Outpatient administration

Intravenous antibiotics may also be administered as part of an outpatient parenteral antibiotic therapy (OPAT) service, which is available in some hospitals. This allows for administration in an outpatient clinic or in a home setting by a district nurse and is for people who require parenteral treatment but are otherwise stable and well enough not to be in hospital. There is currently no NHS reference cost for this service.

A UK study by Chapman 2009³⁰ reports that this type of service costs between 41% and 61% of the equivalent inpatient costs. Based on these estimates from Chapman 2009 and the unit cost for an adult day case in Table 9, the cost of OPAT would be approximately £144 to £215 per day. These costs would include the cost of the drug as well as the administration.

1.6 Resource impact

We do not expect recommendations resulting from this review area to have a significant impact on resources.

1.7 Evidence statements

1.7.1 Clinical evidence statements

Adults and young people:

- Low to Very Low quality evidence from 1 RCT did not find any clinical difference between intravenous ceftriaxone followed by oral doxycycline versus placebo.
- High quality evidence from 1 RCT found a clinical benefit of intravenous ceftriaxone over placebo regarding the improvement in fatigue. Low quality evidence from 1 RCT found a clinical benefit of intravenous ceftriaxone over placebo for the improvement in fatigue as measured by the FSS-11 score. There was no difference between intravenous ceftriaxone and placebo regarding the improvement in cognitive function.
- Low to Very Low quality evidence from 1 RCT did not find any difference between intravenous ceftriaxone followed by oral doxycycline and intravenous ceftriaxone followed by oral clarithromycin and hydroxychloroquine.
- Moderate quality evidence from 1 RCT did not find any difference in quality of life between intravenous ceftriaxone followed by oral doxycycline and intravenous ceftriaxone alone. Moderate quality evidence from 1 RCT showed a higher rate of adverse events for intravenous ceftriaxone followed by oral doxycycline. Low quality evidence from 1 RCT did not find any difference in the number of people discontinuing treatment due to adverse events between the treatment arms.
- Low to Very Low quality evidence did not find any difference between intravenous ceftriaxone followed by oral clarithromycin plus hydroxychloroquine and intravenous ceftriaxone alone.

Children:

- No evidence was found.

1.7.2 Health economic evidence statements

No relevant economic evaluations were identified.

1.8 Recommendations

L1. If symptoms that may be related to Lyme disease persist or worsen after antibiotic treatment, review the person's history and examination to explore:

- any possible alternative causes of the symptoms
- if re-infection may have occurred
- details of any previous treatment, including whether the course of antibiotics was completed without interruption
- if symptoms may be related to organ damage caused by Lyme disease, for example, nerve palsy.

L2. If the person's history suggests re-infection, offer antibiotic treatment according to their symptoms (see recommendations A1-A2 in evidence report D).

- 1 L3. Consider a second course of antibiotics for people with persisting symptoms if treatment
2 may have failed. Use an alternative antibiotic to that used for initial treatment, for
3 example for adults with Lyme disease and arthritis, offer amoxicillin if the person has
4 completed an initial course of doxycycline.
- 5 L4. Do not routinely offer further antibiotics if a person has persisting symptoms following 2
6 courses of antibiotics (see table 30 and table 31 in evidence report D). Consider
7 discussion with or referral to a specialist as outlined in recommendation C10.
- 8 L5. Explain to people with persisting symptoms following antibiotic treatment that:
9
 - 10 • symptoms of Lyme disease may take months to resolve even after treatment
 - 11 • continuing symptoms does not necessarily mean they still have an active infection
 - 12 • symptoms may be a consequence of damage from infection
 - 13 • there may be an alternative diagnosis.
- 14 L6. Support people who have a slow recovery from Lyme disease by:
15
 - 16 • encouraging and helping them to access additional services, including referring to
17 adult social care for a care and support needs assessment, if they would benefit from
18 these
 - 19 • communicating with social services, educational services and employers about the
20 person's need for gradual return to activities, if relevant.

19 **1.8.1 Research recommendations**

20 RR1. What are the incidence, presenting features, management and outcome of Lyme
21 disease, including in women with Lyme disease who are pregnant, in the UK?

22 See also rationale in appendix J of evidence report A.

23 RR2. Can a core outcome set be developed for clinical trials of management of Lyme
24 disease?

25 RR3. What are the most clinically and cost-effective treatment options for different clinical
26 presentations of Lyme disease in the UK?

27 See also rationale in appendix J of evidence report D.

28 **1.9 Rationale and impact**

29 **1.9.1 Why the committee made the recommendations**

30 People who have had treatment for Lyme disease sometimes report persisting symptoms.
31 These may be caused by re-infection, insufficient initial treatment or lack of adherence to
32 treatment, or organ damage caused by Lyme disease, which may take a long time to heal or
33 may even be permanent.

34 The evidence available did not show benefit from prolonged treatment with antibiotics, but
35 the committee agreed that treatment failure could occur and that a second course of
36 antibiotics might sometimes be appropriate. The committee noted the importance of
37 considering alternative diagnoses to prevent inappropriate antibiotic treatment and
38 misdiagnosis.

39 The committee recommended that people with persisting symptoms should not routinely be
40 offered more than 2 courses of antibiotics because of lack of evidence of benefit. However,
41 discussion with a specialist or referral should be considered in some cases.

1 People who have a slow recovery from Lyme disease may need additional support and
2 access to social services. The committee felt that it was important to recommend that
3 healthcare professionals help people with long-term symptoms related to Lyme disease to
4 access support if needed.

5 **1.9.2 Impact of the recommendations on practice**

6 Current treatment for Lyme disease is a single course of antibiotics. Treatment for persisting
7 symptoms is unclear and practice varies. Further antibiotic treatment is now recommended
8 as an option if persisting infection is a possibility. This will standardise practice but may
9 cause an increase in antibiotic prescribing in a small number of patients. The committee
10 agreed that this change in practice would not result in a significant resource impact given the
11 small number of people with recurrent symptoms.

12 **1.10 The committee's discussion of the evidence**

13 **1.10.1 Interpreting the evidence**

14 **1.10.1.1 The outcomes that matter most**

15 The evidence included in this chapter was identified through the review on the management
16 of non-specific symptoms associated with Lyme disease. The identified evidence was in
17 people with Lyme disease who had persistent, non-specific symptoms despite having
18 previous antibiotic treatment. The committee acknowledged that the included studies
19 provided some limited evidence on the effectiveness of long-term antibiotic treatment for
20 Lyme disease.

21 The guideline committee considered quality of life, cure or the resolution of Lyme disease
22 symptoms, the reduction of Lyme disease symptoms, and the relapse of Lyme disease
23 symptoms to be critical outcomes. Adverse events as a result of treatment were considered
24 to be an important outcome.

25 This review only found evidence for the outcomes quality of life, reduction of clinical
26 symptoms and adverse events. No evidence was found for the outcomes cure or resolution
27 of symptoms and symptom relapse.

28 **1.10.1.2 The quality of the evidence**

29 The evidence was generally of Moderate to Very Low quality due to risk of bias, indirectness
30 and imprecision. There were particular concerns around a lack of outcome assessor blinding
31 for subjective outcomes, such as quality of life. One treatment arm in the PLEASE trial also
32 used an indirect intervention as people received hydroxychloroquine in addition to
33 clarithromycin.

34 One outcome, improvement in fatigue for the comparison of intravenous ceftriaxone versus
35 placebo, was of High quality.

36 There were no concerns regarding the risk of bias for any of the outcome reported by the
37 PLEASE trial. However, all participants in the trial received a 2-week course of open-label
38 intravenous ceftriaxone before their assigned study drug. This antibiotic treatment might
39 have resulted in people experiencing a quality of life improvement.

40 There was a general lack of evidence with only single, small studies identified for each
41 comparison. The committee agreed that while the evidence had to be interpreted with
42 caution, there was a trend suggesting that continuous long-term treatment did not provide an
43 additional benefit.

1 1.10.1.3 Benefits and harms

2 The evidence identified was in people with Lyme disease who had persistent non-specific
3 symptoms despite having undergone antibiotic treatment. The majority of the people included
4 in the studies received oral or intravenous antibiotic treatment for their Lyme disease
5 symptoms prior to enrolment in the study.

6 All 3 included studies assessed the effectiveness of intravenous ceftriaxone, alone or in
7 combination with oral doxycycline or oral clarithromycin.

8 The evidence showed a clear benefit of intravenous ceftriaxone (2 grams once daily for 28
9 days) compared to placebo in the improvement of fatigue and quality of life as measured by
10 the FSS-11 score. There was no difference between intravenous ceftriaxone and placebo
11 regarding changes in cognitive function.

12 Two RCTs assessed the effectiveness of intravenous ceftriaxone followed by long-term oral
13 doxycycline or clarithromycin in people with persistent symptoms associated with Lyme
14 disease. In the PLEASE trial, all participants received 2 grams of open-label intravenous
15 ceftriaxone once daily for 14 days before their assigned masked study intervention; either 12
16 weeks of oral doxycycline (100 milligrams twice daily) or 12 weeks of oral clarithromycin (500
17 milligrams clarithromycin plus 200 milligrams hydroxychloroquine twice daily). In the other
18 study, people were randomly assigned 2 grams of intravenous ceftriaxone once daily for 30
19 days followed by 100 milligrams oral doxycycline twice daily for 60 days or a 90-day course
20 of placebo. People with a presumed diagnosis of neuroborreliosis as indicated by a CSF
21 pleocytosis were excluded from this study.

22 Evidence from these 2 RCTs found that the addition of long-term oral doxycycline or oral
23 clarithromycin increased the number of adverse events and led to a significantly higher
24 treatment discontinuation rate due to adverse events. There was, however, no additional
25 benefit of taking long-term oral dosages of doxycycline or clarithromycin after intravenous
26 ceftriaxone on quality of life.

27 1.10.2 Cost effectiveness and resource use

28 No relevant health economic evidence was identified. The unit costs of different oral and
29 intravenous antimicrobials were presented to the committee. The committee agreed it was
30 important to establish if persisting symptoms are related to Lyme disease. This may require
31 additional healthcare practitioner time to allow for a review of history and examination. The
32 committee noted that establishing if a re-infection has occurred would be done clinically not
33 through further testing. Although no cost-effectiveness evidence was identified, it is
34 considered good clinical practice to assess a person with persisting symptoms. Treating
35 people who have been re-infected is considered standard practice for all infections. A
36 recommendation to offer a second course of antibiotics to people with persisting symptoms,
37 who may have treatment failure, was based on the clinical evidence identified and committee
38 discussion as described below. This additional treatment cost is unlikely to apply to a large
39 population and therefore not expected to have a significant resource impact.

40 1.10.3 Other factors the committee took into account

41 The committee considered it important to acknowledge that recovery from infection can take
42 time and this occurs in many infections including Lyme disease.

43 The committee considered evidence from the PLEASE trial to be particularly relevant when
44 developing clinical recommendations for people with persistent symptoms related to Lyme
45 disease. In the study, all participants received open-label intravenous ceftriaxone for 2 weeks
46 followed by their randomly assigned study drug; 12 weeks of oral doxycycline, 12 weeks of
47 oral clarithromycin, or 12 weeks of oral placebo. Although the PLEASE trial showed a quality
48 of life improvement in all treatment arms, there was no difference between treatment arms.

1 The committee considered that any quality of life improvements could be due to the initial 2-
2 week treatment of intravenous ceftriaxone with no clear additional benefit from long-term
3 treatment with oral doxycycline or clarithromycin. To determine the effectiveness of long-term
4 antibiotic treatment, study participants should have also been blinded to the intravenous
5 ceftriaxone treatment, and a fourth treatment arm consisting of only placebo should have
6 been introduced. The committee considered that the evidence did not provide support for
7 long-term antibiotic treatment.

8 The committee also discussed the possibility of treatment failure. Evidence for management
9 of different presentations of Lyme disease all indicated some treatment failures. People
10 respond to treatments differently for various reasons and this is not specific to Lyme disease.
11 The committee agreed that the emphasis on higher doses and 3- or 4-week treatment
12 courses in this guideline should reduce treatment failure but recognised that this can still
13 occur.

14 The committee therefore recommended the consideration of a second course of antibiotic
15 treatment using an alternative antibiotic to the antibiotic initially prescribed if a person has
16 persistent symptoms and treatment failure is suspected.

17 The committee agreed that there was no evidence for further antibiotic treatment beyond
18 this. People with persisting symptoms attributed to Lyme disease despite 2 adequate
19 courses of antibiotics should have their care discussed with a specialist appropriate to their
20 symptoms, for example a rheumatologist if they have joint problems. The committee was
21 concerned about both missing alternate diagnoses and problems caused by inappropriate
22 treatment with antibiotics.

23 The committee also acknowledged that the antibiotic treatment might result in an eradication
24 of the bacteria but may not have any immediate effect on the organ damage. Symptoms
25 associated with organ damage may take a long time to heal or even remain permanent.
26 These symptoms are therefore not necessarily indicative of treatment failure.

27 The committee made a number of high priority research recommendations which include the
28 clinical epidemiology of Lyme disease, the development of a core outcome set for studies of
29 management of Lyme disease, the evaluation of antibiotic regimens for management of
30 Lyme disease. Research in these areas would ensure improved understanding of
31 presentations and treatments for people with persisting symptoms. These research
32 recommendations are outlined in more detail in appendix J of evidence report A and
33 appendix J of evidence report D.

34

1 1.11 Recommendations

2 L7. Assess and offer additional treatment if needed for symptoms of Lyme disease following
3 usual clinical practice (for example, heart block).

4 L8. Be alert to the possibility of symptoms related to Lyme disease that may need
5 assessment and management including:

- 6 • depression and anxiety (see NICE's guideline on common mental health disorders)
- 7 • chronic pain
- 8 • sleep disturbance
- 9 • fatigue.

10 1.12 Rationale and impact

11 1.12.1 Why the committee made the recommendations

12 No specific evidence review was carried out to inform recommendations on support, referral
13 to social services or the need to consider assessing and managing other symptoms related
14 to Lyme disease, such as chronic pain, fatigue or depression. The committee, however,
15 acknowledged that some people with Lyme disease experience a slow recovery and may
16 require professional support. Some people with Lyme disease feel that their needs are not
17 considered in an appropriate way and the committee therefore decided to recommend that
18 physicians consider the possibility of such needs.

19 1.12.2 Impact of the recommendations on practice

20 Some people with Lyme disease may require support or social services, especially when
21 they have a slow recovery. Social services needs assessments are carried out by local
22 authorities and will not affect NHS practice.

23 Some people with Lyme disease may also present with related symptoms, such as chronic
24 pain, depression or fatigue. Guidance for managing these symptoms already exists and
25 therefore there will be no change to existing clinical practice.

1 **1.13 The committee's discussion of the evidence**

2 **1.13.1 Interpreting the evidence**

3 **1.13.1.1 The outcomes that matter most**

4 No specific evidence review was undertaken for the assessment and management of
5 persistent symptoms related to Lyme disease and support of people who have a slow
6 recovery from Lyme disease. The recommendations are based on consensus with regard for
7 the long-term difficulties people with Lyme disease often face.

8 **1.13.1.2 The quality of the evidence**

9 No specific evidence review was undertaken.

10 **1.13.1.3 Benefits and harms**

11 No specific evidence review was undertaken.

12 **1.13.2 Cost effectiveness and resource use**

13 No health economic review was undertaken. Providing information and support towards
14 access to further services such as social care is considered good patient care, particularly in
15 people who experience a slow recovery from illness. In addition, it is considered current
16 practice to assess and manage people for all their presenting symptoms.

17 These recommendations are not expected to apply to all people with Lyme disease and so
18 are not anticipated to have a significant resource impact.

19 **1.13.3 Other factors the committee took into account**

20 The committee discussed the difficulties people with Lyme disease often face, particularly in
21 the absence of a speedy recovery. Although long-term support and the referral to social care
22 services were not part of the scope of this guideline, the committee emphasized that some
23 people may require support, access to social services or a gradual return to work. This is
24 similar to other conditions where recovery is slow, but the committee considered it
25 appropriate to emphasise the need for this in people with Lyme disease.

26 People who have a slow recovery or who experience a significant impact on their personal
27 and professional life may benefit from access to additional services, such as a social services
28 needs assessment.

29 The committee also wished to emphasise the needs of people with Lyme disease for
30 management of symptoms that may need further assessment and management. These
31 symptoms include depression and anxiety, chronic pain, sleep disturbance and fatigue. The
32 committee agreed that these symptoms were not specific to Lyme disease and that guidance
33 on the assessment and management for these already exist. It was therefore decided to
34 highlight the need to consider these symptoms and refer to relevant existing guidance.

References

1. Aberer E, Kahofer P, Binder B, Kinaciyan T, Schauerl H, Berghold A. Comparison of a two- or three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin. *Dermatology*. 2006; 212(2):160-167
2. Abrutyn E. New uses for old drugs. *Infectious Disease Clinics of North America*. 1989; 3(3):653-664
3. Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of *Borrelia burgdorferi* to five oral cephalosporins and ceftriaxone. *Antimicrobial Agents and Chemotherapy*. 1992; 36(8):1788-1790
4. Agus B. The recognition and treatment of Lyme disease. *Primary Care Update for Ob/Gyns*. 1995; 2(6):200-203
5. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylicyclines. *Journal of Antimicrobial Chemotherapy*. 2006; 58(2):256-265
6. Ahmed A. When is facial paralysis Bell palsy? current diagnosis and treatment. *Cleveland Clinic Journal of Medicine*. 2005; 72(5):398-405
7. Ahmed S, Rashid S, Chaudhary A, Bischof E. A patient with Lyme disease: complete heart block treated with antibiotics. *Primary Care Cardiovascular Journal*. 2013; 6(3):117-118
8. Alarcon GS, Mikhail IS. Antimicrobials in the treatment of rheumatoid arthritis and other arthritides: a clinical perspective. *American Journal of the Medical Sciences*. 1994; 308(3):201-209
9. Andiman WA. Lyme disease: epidemiology, etiology, clinical spectrum, diagnosis, and treatment. *Advances in Pediatric Infectious Diseases*. 1986; 1:163-186
10. Anonymous. Antibiotic prophylaxis of Lyme disease following recognized tick bite. Bacterial Zoonoses Branch, Division of Vector-Borne Infectious Diseases National Center for Infectious Diseases, Centers for Disease Control. *Connecticut Medicine*. 1991; 55(12):691-693
11. Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. *Infectious Disease Clinics of North America*. 2015; 29(2):269-280
12. Auwaerter PG, Aucott J, Dumler JS. Lyme borreliosis (Lyme disease): molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment. *Expert Reviews in Molecular Medicine*. 2004; 6(2):1-22
13. Bennet L, Danell S, Berglund J. Clinical outcome of erythema migrans after treatment with phenoxymethyl penicillin. *Scandinavian Journal of Infectious Diseases*. 2003; 35(2):129-131
14. Berende A, ter Hofstede HJ, Donders AR, van Middendorp H, Kessels RP, Adang EM et al. Persistent Lyme Empiric Antibiotic Study Europe (PLEASE)--design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis. *BMC Infectious Diseases*. 2014; 14:543
15. Berende A, ter Hofstede HJ, Vos FJ, van Middendorp H, Vogelaar ML, Tromp M et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. *New England Journal of Medicine*. 2016; 374(13):1209-1220

- 1 16. Berger BW. Treating erythema chronicum migrans of Lyme disease. *Journal of the*
2 *American Academy of Dermatology*. 1986; 15(3):459-463
- 3 17. Berger BW. Treatment of erythema chronicum migrans of Lyme disease. *Annals of*
4 *the New York Academy of Sciences*. 1988; 539:346-351
- 5 18. Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline
6 inhibit the inflammatory responses to the Lyme disease spirochete *Borrelia*
7 *burgdorferi*. *Journal of Infectious Diseases*. 2009; 199(9):1379-1388
- 8 19. Bhate C, Schwartz RA. Lyme disease: Part II. Management and prevention. *Journal*
9 *of the American Academy of Dermatology*. 2011; 64(4):639-653
- 10 20. Bjark PH. Re: No prolonged antibiotic therapy for disease attributed to borreliosis.
11 *Tidsskrift for den Norske Laegeforening*. 2016; 136(20):1702-1703
- 12 21. BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National
13 Formulary. Available from: <https://www.evidence.nhs.uk/formulary/bnf/current> Last
14 accessed: 04 April 2017.
- 15 22. BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National
16 Formulary for Children. Available from:
17 <https://www.evidence.nhs.uk/formulary/bnf/current> Last accessed: 04 April 2017.
- 18 23. Borg R, Dotevall L, Hagberg L, Maraspin V, Lotric-Furlan S, Cimperman J et al.
19 Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme
20 neuroborreliosis. *Scandinavian Journal of Infectious Diseases*. 2005; 37(6-7):449-454
- 21 24. Bratton RL, Whiteside JW, Hovan MJ, Engle RL, Edwards FD. Diagnosis and
22 treatment of lyme disease. *Mayo Clinic Proceedings*. 2008; 83(5):566-571
- 23 25. Bremell D, Dotevall L. Oral doxycycline for Lyme neuroborreliosis with symptoms of
24 encephalitis, myelitis, vasculitis or intracranial hypertension. *European Journal of*
25 *Neurology*. 2014; 21(9):1162-1167
- 26 26. British Infection Association. The epidemiology, prevention, investigation and
27 treatment of Lyme borreliosis in United Kingdom patients: A position statement by the
28 British Infection Association. *Journal of Infection*. 2011; 62(5):329-338
- 29 27. Butler T, Jones PK, Wallace CK. *Borrelia recurrentis* infection: single-dose antibiotic
30 regimens and management of the Jarisch-Herxheimer reaction. *Journal of Infectious*
31 *Diseases*. 1978; 137(5):573-577
- 32 28. Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H. Antibiotics for the
33 neurological complications of Lyme disease. *Cochrane Database of Systematic*
34 *Reviews* 2016, Issue 12. Art. No.: CD006978. DOI:
35 10.1002/14651858.CD006978.pub2.
- 36 29. Canadian Paediatric Society. How to diagnose and treat Lyme disease in children.
37 *Infectious Diseases and Immunization Committee, Canadian Paediatric Society.*
38 *CMAJ*. 1992; 147(2):169-178
- 39 30. Chapman AL, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD. Clinical efficacy
40 and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK
41 perspective. *Journal of Antimicrobial Chemotherapy*. 2009; 64(6):1316-1324
- 42 31. Chen J, Field JA, Glickstein L, Molloy PJ, Huber BT, Steere AC. Association of
43 antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant
44 epitopes of outer surface protein a of *Borrelia burgdorferi*. *Arthritis and Rheumatism*.
45 1999; 42(9):1813-1822

- 1 32. Choo-Kang C, Tang E, Mattappallil A. The treatment of early lyme disease. US
2 Pharmacist. 2010; 35(9):41-48
- 3 33. Christian CL. Management of asymptomatic *Borrelia burgdorferi* infection. Arthritis
4 and Rheumatism. 1992; 35(11):1395
- 5 34. Cimmino MA. Recognition and management of bacterial arthritis. Drugs. 1997;
6 54(1):50-60
- 7 35. Cimmino MA, Accardo S. Long term treatment of chronic Lyme arthritis with
8 benzathine penicillin. Annals of the Rheumatic Diseases. 1992; 51(8):1007-1008
- 9 36. Cimperman J, Maraspin V, Lotric-Furlan S, Ruzic-Sabljić E, Strle F. Lyme meningitis:
10 a one-year follow up controlled study. Wiener Klinische Wochenschrift. 1999; 111(22-
11 23):961-963
- 12 37. Coblyn JS, Taylor P. Treatment of chronic Lyme arthritis with hydroxychloroquine.
13 Arthritis and Rheumatism. 1981; 24(12):1567-1569
- 14 38. Commercial Medicines Unit (CMU), Department of Health. Electronic market
15 information tool (EMIT). 2011. Available from: [http://cmu.dh.gov.uk/electronic-market-](http://cmu.dh.gov.uk/electronic-market-information-tool-emit/)
16 [information-tool-emit/](http://cmu.dh.gov.uk/electronic-market-information-tool-emit/) Last accessed: 4 April 2017.
- 17 39. Committee on Infectious Diseases. Erratum: Treatment of lyme borreliosis (Pediatrics
18 (July 1991) 88 (7-19)). Pediatrics. 1991; 88(4):840
- 19 40. Cuisset T, Hamilos M, Vanderheyden M. Coronary aneurysm in Lyme disease:
20 treatment by covered stent. International Journal of Cardiology. 2008; 128(2):e72-e73
- 21 41. Curtis L, Burns A. Unit costs of health and social care 2016. Canterbury. Personal
22 Social Services Research Unit University of Kent, 2016. Available from:
23 <http://www.pssru.ac.uk/project-pages/unit-costs/2016/>
- 24 42. Dattwyler RJ, Grunwaldt E, Luft BJ. Clarithromycin in treatment of early Lyme
25 disease: a pilot study. Antimicrobial Agents and Chemotherapy. 1996; 40(2):468-469
- 26 43. Dattwyler RJ, Halperin JJ. Failure of tetracycline therapy in early Lyme disease.
27 Arthritis and Rheumatism. 1987; 30(4):448-450
- 28 44. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis -
29 randomised comparison of ceftriaxone and penicillin. Lancet. 1988; 1(8596):1191-
30 1194
- 31 45. Dattwyler RJ, Wormser GP, Rush TJ, Finkel MF, Schoen RT, Grunwaldt E et al. A
32 comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wiener
33 Klinische Wochenschrift. 2005; 117(11-12):393-397
- 34 46. Department of Health. NHS reference costs 2015-16. 2016. Available from:
35 [https://www.gov.uk/government/publications/nhs-reference-costs-collection-guidance-](https://www.gov.uk/government/publications/nhs-reference-costs-collection-guidance-for-2015-to-2016)
36 [for-2015-to-2016](https://www.gov.uk/government/publications/nhs-reference-costs-collection-guidance-for-2015-to-2016) Last accessed: 4 April 2017.
- 37 47. Dersch R, Freitag MH, Schmidt S, Sommer H, Rauer S, Meerpohl JJ. Efficacy and
38 safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic
39 review. European Journal of Neurology. 2015; 22(9):1249-1259
- 40 48. Dersch R, Freitag MH, Schmidt S, Sommer H, Rucker G, Rauer S et al. Efficacy and
41 safety of pharmacological treatments for neuroborreliosis--protocol for a systematic
42 review. Systems Review. 2014; 3:117
- 43 49. Dersch R, Rauer S. Treatment and long-term outcome of Lyme neuroborreliosis.
44 Aktuelle neurologie. 2017; 43(10):608-614

- 1 50. Dersch R, Sommer H, Rauer S, Meerpohl JJ. Prevalence and spectrum of residual
2 symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic
3 review. *Journal of Neurology*. 2016; 263(1):17-24
- 4 51. Dhoot DS, Martin DF, Srivastava SK. Pediatric infectious posterior uveitis.
5 *International Ophthalmology Clinics*. 2011; 51(1):113-128
- 6 52. Dinser R, Jendro MC, Schnarr S, Zeidler H. Antibiotic treatment of Lyme borreliosis:
7 what is the evidence? *Annals of the Rheumatic Diseases*. 2005; 64(4):519-523
- 8 53. Dotevall L, Alestig K, Hanner P, Norkrans G, Hagberg L. The use of doxycycline in
9 nervous system *Borrelia burgdorferi* infection. *Scandinavian Journal of Infectious
10 Diseases Supplement*. 1988; 53:74-79
- 11 54. Eliassen KE, Berild D, Reiso H, Grude N, Christophersen KS, Finckenhagen C et al.
12 Incidence and antibiotic treatment of erythema migrans in Norway 2005-2009. *Ticks
13 and Tick-Borne Diseases*. 2017; 8(1):1-8
- 14 55. Eliassen KE, Hjetland R, Reiso H, Lindbaek M, Tschudi-Madsen H. Symptom load
15 and general function among patients with erythema migrans: a prospective study with
16 a 1-year follow-up after antibiotic treatment in Norwegian general practice.
17 *Scandinavian Journal of Primary Health Care*. 2017; 35(1):75-83
- 18 56. Eppes SC. Diagnosis, treatment, and prevention of Lyme disease in children.
19 *Pediatric Drugs*. 2003; 5(6):363-372
- 20 57. Esposito S, Baggi E, Villani A, Norbedo S, Pellegrini G, Bozzola E et al. Management
21 of paediatric Lyme disease in non-endemic and endemic areas: data from the registry
22 of the Italian Society for Pediatric Infectious Diseases. *European Journal of Clinical
23 Microbiology and Infectious Diseases*. 2013; 32(4):523-529
- 24 58. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E et al. A
25 randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme
26 encephalopathy. *Neurology*. 2008; 70(13):992-1003
- 27 59. Fallon BA, Tager F, Fein L, Liegner K, Keilp J, Weiss N et al. Repeated antibiotic
28 treatment in chronic Lyme disease. *Journal of Spirochetal and Tick-borne Diseases*.
29 1999; 6(4):94-102
- 30 60. Galev A, Zvetkov V, Genov K. Pulse therapy with ceftriaxone on Lyme
31 neuroborreliosis. *Problems of Infectious and Parasitic Diseases*. 2005; 33(1):15-17
- 32 61. Garkowski A, Zajkowska J, Zajkowska A, Kulakowska A, Zajkowska O, Kubas B et al.
33 Cerebrovascular manifestations of Lyme neuroborreliosis-a systematic review of
34 published cases. *Frontiers in Neurology*. 2017; 8:146
- 35 62. Gasser R, Reisinger E, Eber B, Pokan R, Seinost G, Bergloff J et al. Cases of Lyme
36 borreliosis resistant to conventional treatment: improved symptoms with
37 cephalosporin plus specific beta-lactamase inhibition. *Microbial Drug Resistance*.
38 1995; 1(4):341-344
- 39 63. Gasser R, Reisinger E, Sedaj B, Horvarth R, Seinost G, Keplinger A et al. Oral
40 treatment of late Lyme borreliosis with a combination of roxithromycin and co-
41 trimoxazole--a pilot study on 18 patients. *Acta Medica Austriaca*. 1996; 23(3):99-101
- 42 64. Gasser R, Wendelin I, Reisinger E, Bergloff J, Feigl B, Schafhalter I et al.
43 Roxithromycin in the treatment of Lyme disease--update and perspectives. *Infection*.
44 1995; 23 (Suppl.1):S39-43

- 1 65. Gerber MA, Shapiro ED, Burke GS, Parcels VJ, Bell GL. Lyme disease in children in
2 southeastern Connecticut. *Pediatric Lyme Disease Study Group. New England*
3 *Journal of Medicine*. 1996; 335(17):1270-1274
- 4 66. Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glasziou P et al.
5 Common harms from amoxicillin: a systematic review and meta-analysis of
6 randomized placebo-controlled trials for any indication. *CMAJ*. 2015; 187(1):E21-E31
- 7 67. Goodwin SD, Sproat TT, Russell WL. Management of Lyme disease. *Clinical*
8 *Pharmacy*. 1990; 9(3):192-205
- 9 68. Hansen K, Hovmark A, Lebech AM, Lebech K, Olsson I, Halkier-Sørensen L et al.
10 Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal
11 susceptibility study and a clinical trial in patients with erythema migrans. *Acta*
12 *Dermato-Venereologica*. 1992; 72(4):297-300
- 13 69. Hassler D, Zoller L, Haude M, Hufnagel HD, Heinrich F, Sonntag HG. Cefotaxime
14 versus penicillin in the late stage of Lyme disease: prospective, randomized
15 therapeutic study. *Infection*. 1990; 18(1):16-20
- 16 70. Horton DB, Taxter AJ, Groh B, Sherry DD, Rose CD. Clinical and treatment factors
17 associated with antibiotic-refractory Lyme arthritis in children. *Arthritis and*
18 *Rheumatology*. 2017; 68(S10):3140-3143
- 19 71. Hu LT, Klempner MS. Update on the prevention, diagnosis, and treatment of Lyme
20 disease. *Advances in Internal Medicine*. 2001; 46:247-275
- 21 72. Inboriboon PC. Early recognition and management of Lyme carditis. *International*
22 *Journal of Emergency Medicine*. 2010; 3(4):489-490
- 23 73. Kaplan RF, Trevino RP, Johnson GM, Levy L, Dornbush R, Hu LT et al. Cognitive
24 function in post-treatment Lyme disease: do additional antibiotics help? *Neurology*.
25 2003; 60(12):1916-1922
- 26 74. Karkkonen K, Stiernstedt SH, Karlsson M. Follow-up of patients treated with oral
27 doxycycline for Lyme neuroborreliosis. *Scandinavian Journal of Infectious Diseases*.
28 2001; 33(4):259-262
- 29 75. Karlsson M, Hammers S, Nilsson-Ehle I, Malmberg AS, Wretling B. Concentrations of
30 doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for
31 neuroborreliosis. *Antimicrobial Agents and Chemotherapy*. 1996; 40(5):1104-1107
- 32 76. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and
33 doxycycline on morphology of *Borrelia burgdorferi*. *Antimicrobial Agents and*
34 *Chemotherapy*. 1995; 39(5):1127-1133
- 35 77. Kilic Muftuoglu I, Aydin Akova Y, Gur Gungor S. A case of Lyme disease
36 accompanied by uveitis and white dot syndrome. *Turkish Journal of Ophthalmology*.
37 2016; 46(5):241-243
- 38 78. Klempner MS. Controlled trials of antibiotic treatment in patients with post-treatment
39 chronic Lyme disease. *Vector Borne and Zoonotic Diseases*. 2002; 2(4):255-263
- 40 79. Klempner MS, Baker PJ, Shapiro ED, Marques A, Dattwyler RJ, Halperin JJ et al.
41 Treatment trials for post-lyme disease symptoms revisited. *American Journal of*
42 *Medicine*. 2013; 126(8):665-669
- 43 80. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP et al. Two
44 controlled trials of antibiotic treatment in patients with persistent symptoms and a
45 history of Lyme disease. *New England Journal of Medicine*. 2001; 345(2):85-92

- 1 81. Korenberg EI, Vorobyeva NN, Moskvitina HG, Gorban Ln. Prevention of borreliosis in
2 persons bitten by infected ticks. *Infection*. 1996; 24(2):187-189
- 3 82. Kowalski TJ, Berth WL, Mathiason MA, Agger WA. Oral antibiotic treatment and long-
4 term outcomes of Lyme facial nerve palsy. *Infection*. 2011; 39(3):239-245
- 5 83. Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA. Antibiotic treatment
6 duration and long-term outcomes of patients with early Lyme disease from a Lyme
7 disease-hyperendemic area. *Clinical Infectious Diseases*. 2010; 50(4):512-520
- 8 84. Krbkova L, Stanek G. Therapy of Lyme borreliosis in children. *Infection*. 1996;
9 24(2):170-173
- 10 85. Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S et al. Study and
11 treatment of post Lyme disease (STOP-LD): a randomized double masked clinical
12 trial. *Neurology*. 2003; 60(12):1923-1930
- 13 86. Kuhn M, Grave S, Bransfield R, Harris S. Long term antibiotic therapy may be an
14 effective treatment for children co-morbid with Lyme disease and autism spectrum
15 disorder. *Medical Hypotheses*. 2012; 78(5):606-615
- 16 87. Laasila K, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term
17 prognosis of reactive arthritis. *Annals of the Rheumatic Diseases*. 2003; 62(7):655-
18 658
- 19 88. Lantos PM, Brinkerhoff RJ, Wormser GP, Clemen R. Empiric antibiotic treatment of
20 erythema migrans-like skin lesions as a function of geography: a clinical and cost
21 effectiveness modeling study. *Vector Borne and Zoonotic Diseases*. 2013;
22 13(12):877-883
- 23 89. Lauhio A, Konttinen YT, Salo T, Tschesche H, Lahdevirta J, Woessner FJ et al.
24 Placebo-controlled study of the effects of three-month lymecyclille treatment on
25 serum matrix metalloproteinases in reactive arthritis. *Annals of the New York
26 Academy of Sciences*. 1994; 732:424-426
- 27 90. Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-
28 controlled study of three-month treatment with lymecycline in reactive arthritis, with
29 special reference to Chlamydia arthritis. *Arthritis and Rheumatism*. 1991; 34(1):6-14
- 30 91. Liegner KB. Minocycline in Lyme disease. *Journal of the American Academy of
31 Dermatology*. 1992; 26(2 Pt 1):263-264
- 32 92. Lipsker D, Antoni-Bach N, Hansmann Y, Jaulhac B. Long-term prognosis of patients
33 treated for erythema migrans in France. *British Journal of Dermatology*. 2002;
34 146(5):872-876
- 35 93. Ljostad U, Eikeland R, Midgard R, Skogvoll E, Skarpass T, Berg A. Oral doxycycline
36 vs. IV centriaxone for European Lyme neuro-borreliosis. A double-blind, randomized
37 controlled clinical trial. *European Journal of Neurology*. 2008; 15(Suppl 3):338-389
- 38 94. Loewen PS, Marra CA, Marra F. Systematic review of the treatment of early Lyme
39 disease *Drugs*. 1999; 57(2):157-173
- 40 95. Loewen PS, Marra CA, Marra F. Erratum: Systemic review of the treatment of early
41 Lyme disease (*Drugs* (1999) 57 (2) (157-173)). *Drugs*. 2000; 59(3):476
- 42 96. Luft BJ, Halperin JJ, Volkman DJ, Dattwyler RJ. Ceftriaxone -an effective treatment of
43 late Lyme borreliosis. *Journal of Chemotherapy*. 1989; 1(Suppl 4):917-919

- 1 97. Luft BJ, Volkman DJ, Halperin JJ, Dattwyler RJ. New chemotherapeutic approaches
2 in the treatment of Lyme borreliosis. *Annals of the New York Academy of Sciences*.
3 1988; 539:352-361
- 4 98. Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F. Treatment of
5 erythema migrans in pregnancy. *Clinical Infectious Diseases*. 1996; 22(5):788-793
- 6 99. Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F. Erythema
7 migrans in pregnancy. *Wiener Klinische Wochenschrift*. 1999; 111(22-23):933-940
- 8 100. Maraspin V, Cimperman J, Lotric-Furlan S, Ruzic-Sabljić E, Jurca T, Picken RN et al.
9 Solitary borrelial lymphocytoma in adult patients. *Wiener Klinische Wochenschrift*.
10 2002; 114(13-14):515-523
- 11 101. Maraspin V, Lotric-Furlan S, Cimperman J, Ruzic-Sabljić E, Strle F. Erythema
12 migrans in the immunocompromised host. *Wiener Klinische Wochenschrift*. 1999;
13 111(22-23):923-932
- 14 102. Maraspin V, Lotric-Furlan S, Strle F. Development of erythema migrans in spite of
15 treatment with antibiotics after a tick bite. *Wiener Klinische Wochenschrift*. 2002;
16 114(13-14):616-619
- 17 103. Maraspin V, Ruzic-Sabljić E, Strle F, Cimperman J, Jereb M, Preac-Mursic V.
18 Persistence of *Borrelia burgdorferi* after treatment with antibiotics. *Alpe Adria*
19 *Microbiology Journal*. 1995; 4(3):211-216
- 20 104. Marks CM, Nawn JE, Caplow JA. Antibiotic treatment for chronic Lyme disease -say
21 no to the DRESS. *JAMA Internal Medicine*. 2016; 176(12):1745-1746
- 22 105. McGill IG, Bienenstock J. A comparative clinical trial of lymecycline. *British Journal of*
23 *Clinical Practice*. 1965; 19:462-464
- 24 106. Meyerhoff J. Prolonged antibiotic treatment did not relieve chronic symptoms in Lyme
25 disease. *ACP Journal Club*. 2002; 136(2):57
- 26 107. Meyerhoff J. Long-term antibiotics after ceftriaxone did not improve quality of life in
27 persistent Lyme disease. *Annals of Internal Medicine*. 2016; 165(2):JC5
- 28 108. Millner MM, Thalhammer GH. Neuroborreliosis in childhood: treatment with penicillin
29 sodium and ceftriaxone. *Acta Dermatovenerologica Alpina, Panonica et Adriatica*.
30 1996; 5(3-4):169-172
- 31 109. Millner MM, Thalhammer GH, Dittrich P, Spork KD, Brunner M, Georgopoulos A.
32 Beta-lactam antibiotics in the treatment of neuroborreliosis in children: preliminary
33 results. *Infection*. 1996; 24(2):174-177
- 34 110. Morales DS, Siatkowski RM, Howard CW, Warman R. Optic neuritis in children.
35 *Journal of Pediatric Ophthalmology and Strabismus*. 2000; 37(5):254-259
- 36 111. Muellegger R, Zöchling N, Schluëpen EM, Soyer HP, Hoedl S, Kerl et al.
37 Polymerase chain reaction control of antibiotic treatment in dermatoborreliosis.
38 *Infection*. 1996; 24(1):76-79
- 39 112. Muellegger RR, Zöchling N, Soyer HP, Hoedl S, Wienecke R, Volkenandt M et al.
40 No detection of *Borrelia burgdorferi*-specific DNA in erythema migrans lesions after
41 minocycline treatment. *Archives of Dermatology*. 1995; 131(6):678-682
- 42 113. Müllegger RR, Millner MM, Stanek G, Spork KD. Penicillin G sodium and ceftriaxone
43 in the treatment of neuroborreliosis in children--a prospective study. *Infection*. 1991;
44 19(4):279-283

- 1 114. Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D et al.
2 Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an
3 Ixodes scapularis tick bite. *New England Journal of Medicine*. 2001; 345(2):79-84
- 4 115. Nadelman RB, Nowakowski J, Forseter G, Bittker S, Cooper D, Goldberg N et al.
5 Failure to isolate *Borrelia burgdorferi* after antimicrobial therapy in culture-
6 documented Lyme borreliosis associated with erythema migrans: report of a
7 prospective study. *American Journal of Medicine*. 1993; 94(6):583-588
- 8 116. Naglo AS, Wide K. *Borrelia* infection in children. *Acta Paediatrica Scandinavica*.
9 1989; 78(6):918-922
- 10 117. National Collaborating Centre for Women's and Children's Health. Meningitis
11 (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and
12 management. NICE clinical guideline 102. London. RCOG Press, 2010. Available
13 from: <http://guidance.nice.org.uk/CG102>
- 14 118. National Institute for Health and Care Excellence. Developing NICE guidelines: the
15 manual. London. National Institute for Health and Care Excellence, 2014. Available
16 from:
17 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
- 18 119. Neumann R, Aberer E, Stanek G. Treatment and course of erythema chronicum
19 migrans. *Zentralblatt für Bakteriologie, Mikrobiologie, und Hygiene - Series A, Medical*
20 *Microbiology, Infectious Diseases, Virology, Parasitology*. 1987; 263(3):372-376
- 21 120. NHS Business Services Authority. NHS electronic drug tariff March 2017. Available
22 from: http://www.drugtariff.nhsbsa.nhs.uk/#/00446515-DC_2/DC00446511/Home Last
23 accessed: 4 April 2017.
- 24 121. Nimmrich S, Becker I, Horneff G. Intraarticular corticosteroids in refractory childhood
25 Lyme arthritis. *Rheumatology International*. 2014; 34(7):987-994
- 26 122. Nowakowski J, McKenna D, Nadelman RB, Cooper D, Bittker S, Holmgren D et al.
27 Failure of treatment with cephalexin for Lyme disease. *Archives of Family Medicine*.
28 2000; 9(6):563-567
- 29 123. Nowakowski J, Nadelman RB, Forseter G, McKenna D, Wormser GP. Doxycycline
30 versus tetracycline therapy for Lyme disease associated with erythema migrans.
31 *Journal of the American Academy of Dermatology*. 1995; 32(2 Pt 1):223-227
- 32 124. Ogrinc K, Logar M, Lotric-Furlan S, Cerar D, Ruzic-Sabljić E, Strle F. Doxycycline
33 versus ceftriaxone for the treatment of patients with chronic Lyme borreliosis. *Wiener*
34 *Klinische Wochenschrift*. 2006; 118(21):696-701
- 35 125. Oksi J, Marjamäki M, Nikoskelainen J, Viljanen MK. *Borrelia burgdorferi* detected by
36 culture and PCR in clinical relapse of disseminated Lyme borreliosis. *Annals of*
37 *Medicine*. 1999; 31(3):225-232
- 38 126. Oksi J, Nikoskelainen J, Hiekkänen H, Lauhio A, Peltomaa M, Pitkäranta A et al.
39 Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind,
40 randomized, placebo-controlled, multicenter clinical study. *European Journal of*
41 *Clinical Microbiology and Infectious Diseases*. 2007; 26(8):571-581
- 42 127. Oksi J, Nikoskelainen J, Viljanen MK. Comparison of oral cefixime and intravenous
43 ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis. *European*
44 *Journal of Clinical Microbiology and Infectious Diseases*. 1998; 17(10):715-719

- 1 128. Peltomaa M, Saxen H, Seppala I, Viljanen M, Pyykko I. Paediatric facial paralysis
2 caused by Lyme borreliosis: a prospective and retrospective analysis. *Scandinavian*
3 *Journal of Infectious Diseases*. 1998; 30(3):269-275
- 4 129. Pena CA, Mathews AA, Siddiqi NH, Strickland GT. Antibiotic therapy for lyme disease
5 in a population-based cohort. *Clinical Infectious Diseases*. 1999; 29(3):694-695
- 6 130. Perronne C. Critical review of studies trying to evaluate the treatment of chronic Lyme
7 disease. *Presse Medicale*. 2015; 44(7-8):828-831
- 8 131. Pfister HW, Einhaupl KM, Franz P, Garner C. Corticosteroids for radicular pain in
9 Bannwarth's syndrome: a double-blind, randomized, placebo-controlled trial. *Annals*
10 *of the New York Academy of Sciences*. 1988; 539(1):485-487
- 11 132. Pfister HW, Preac-Mursic V, Wilske B, Einhäupl KM. Cefotaxime vs penicillin G for
12 acute neurologic manifestations in Lyme borreliosis. A prospective randomized study.
13 *Archives of Neurology*. 1989; 46(11):1190-1194
- 14 133. Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KM.
15 Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
16 *Journal of Infectious Diseases*. 1991; 163(2):311-318
- 17 134. Pirila V. The penicillin treatment of acrodermatitis atrophicans chronica. *Acta*
18 *Dermato-Venereologica*. 1951; 31(5):576-591
- 19 135. Plorer A, Sepp N, Schmutzhard E, Krabichler S, Trobos S, Schauer G et al. Effects of
20 adequate versus inadequate treatment of cutaneous manifestations of Lyme
21 borreliosis on the incidence of late complications and late serologic status. *Journal of*
22 *Investigative Dermatology*. 1993; 100(2):103-109
- 23 136. Plotkin SA, Peter G. Treatment of Lyme borreliosis. *Pediatrics*. 1991; 88(1):176-179
- 24 137. Puchalska B, Niemcunowicz-Janica A, Kondej Muszynska K, Trippner M. Lyme
25 borreliosis--tick borne spirochaetosis among children. *Roczniki Akademii Medycznej*
26 *w Bialymstoku (1995)*. 1996; 41(1):59-61
- 27 138. Puri BK, Hakkarainen-Smith JS, Derham A, Monro JA. Co-administration of alpha-
28 lipoic acid and glutathione is associated with no significant changes in serum bilirubin,
29 alkaline phosphatase or gamma-glutamyltranspeptidase levels during the treatment
30 of neuroborreliosis with intravenous ceftriaxone. *Journal of Complementary and*
31 *Integrative Medicine*. 2015; 12(3):227-230
- 32 139. Puri BK, Hakkarainen-Smith JS, Monro JA. The potential use of cholestyramine to
33 reduce the risk of developing *Clostridium difficile*-associated diarrhoea in patients
34 receiving long-term intravenous ceftriaxone. *Medical Hypotheses*. 2015; 84(1):78-80
- 35 140. Rebman AW, Crowder LA, Kirkpatrick A, Aucott JN. Characteristics of seroconversion
36 and implications for diagnosis of post-treatment Lyme disease syndrome: acute and
37 convalescent serology among a prospective cohort of early Lyme disease patients.
38 *Clinical Rheumatology*. 2015; 34(3):585-589
- 39 141. Renaud I, Cachin C, Gerster JC. Good outcomes of Lyme arthritis in 24 patients in an
40 endemic area of Switzerland. *Joint, Bone, Spine: Revue du Rhumatisme*. 2004;
41 71(1):39-43
- 42 142. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J. Ceftriaxone in the treatment of
43 Lyme neuroborreliosis. *Infection*. 1996; 24(1):88-90

- 1 143. Rose CD, Fawcett PT, Eppes SC, Klein JD, Gibney K, Doughty RA. Pediatric Lyme
2 arthritis: clinical spectrum and outcome. *Journal of Pediatric Orthopaedics*. 1994;
3 14(2):238-241
- 4 144. Rose CD, Fawcett PT, Gibney KM, Doughty RA. Residual serologic reactivity in
5 children with resolved Lyme arthritis. *Journal of Rheumatology*. 1996; 23(2):367-369
- 6 145. Rubin DA, Sorbera C, Nikitin P, McAllister A, Wormser GP, Nadelman RB.
7 Prospective evaluation of heart block complicating early Lyme disease. *PACE -*
8 *Pacing and Clinical Electrophysiology*. 1992; 15(3):252-255
- 9 146. Salazar CA, Rothemich M, Drouin EE, Glickstein L, Steere AC. Human Lyme arthritis
10 and the immunoglobulin G antibody response to the 37-kilodalton arthritis-related
11 protein of *Borrelia burgdorferi*. *Infection and Immunity*. 2005; 73(5):2951-2957
- 12 147. Salazar JC, Gerber MA, Goff CW. Long-term outcome of Lyme disease in children
13 given early treatment. *Journal of Pediatrics*. 1993; 122(4):591-593
- 14 148. Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of
15 Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. *JAMA*.
16 2016; 315(16):1767-1777
- 17 149. Sandstrom M, Bredberg G, Asbrink E, Hovmark A, Holmkvist C. Brainstem response
18 audiometry in chronic Lyme borreliosis. *Scandinavian Audiology*. 1989; 18(4):205-210
- 19 150. Schmidt BL, Aberer E, Stockenhuber C, Klade H, Breier F, Luger A. Detection of
20 *Borrelia burgdorferi* DNA by polymerase chain reaction in the urine and breast milk of
21 patients with Lyme borreliosis. *Diagnostic Microbiology and Infectious Disease*. 1995;
22 21(3):121-128
- 23 151. Selby G, Bridges SJ, Hanington L. Should Lyme disease affecting the nervous
24 system be treated with oral or intravenous antibiotics? *Archives of Disease in*
25 *Childhood Education & Practice*. 2008; 93(4):132-134
- 26 152. Shadick NA, Phillips CB, Logigian EL, Steere AC, Kaplan RF, Berardi VP et al. The
27 long-term clinical outcomes of Lyme disease. A population-based retrospective cohort
28 study. *Annals of Internal Medicine*. 1994; 121(8):560-567
- 29 153. Shadick NA, Phillips CB, Sangha O, Logigian EL, Kaplan RF, Wright EA et al.
30 Musculoskeletal and neurologic outcomes in patients with previously treated Lyme
31 disease. *Annals of Internal Medicine*. 1999; 131(12):919-926
- 32 154. Shemenski J. Cimetidine as a novel adjunctive treatment for early stage Lyme
33 disease. *Medical Hypotheses*. 2016; Epublication
- 34 155. Shoemaker RC, Hudnell HK, House DE, Kempen A, Pakes GE. Atovaquone plus
35 cholestyramine in patients coinfecting with *Babesia microti* and *Borrelia burgdorferi*
36 refractory to other treatment. *Advances in Therapy*. 2006; 23(1):1-11
- 37 156. Sjöwall J, Fryland L, Nordberg M, Sjogren F, Garpmo U, Jansson C et al. Decreased
38 Th1-type inflammatory cytokine expression in the skin is associated with persisting
39 symptoms after treatment of erythema migrans. *PloS One*. 2011; 6(3):e18220
- 40 157. Sjöwall J, Ledel A, Ernerudh J, Ekerfelt C, Forsberg P. Doxycycline-mediated effects
41 on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a
42 randomized, prospective, cross-over study. *BMC Infectious Diseases*. 2012; 12:186
- 43 158. Skogman BH, Croner S, Nordwall M, Eknefelt M, Ernerudh J, Forsberg P. Lyme
44 neuroborreliosis in children: a prospective study of clinical features, prognosis, and
45 outcome. *Pediatric Infectious Disease Journal*. 2008; 27(12):1089-1094

- 1 159. Skogman BH, Croner S, Odkvist L. Acute facial palsy in children - a 2-year follow-up
2 study with focus on Lyme neuroborreliosis. *International Journal of Pediatric*
3 *Otorhinolaryngology*. 2003; 67(6):597-602
- 4 160. Skoldenberg B, Stiernstedt G, Karlsson M, Wretling B, Svenungsson B. Treatment of
5 Lyme borreliosis with emphasis on neurological disease. *Annals of the New York*
6 *Academy of Sciences*. 1988; 539:317-323
- 7 161. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL et al.
8 Clinical characteristics and treatment outcome of early Lyme disease in patients with
9 microbiologically confirmed erythema migrans. *Annals of Internal Medicine*. 2002;
10 136(6):421-428
- 11 162. Solomon SP, Hilton E, Weinschel BS, Pollack S, Grolnick E. Psychological factors in
12 the prediction of Lyme disease course. *Arthritis Care and Research*. 1998; 11(5):419-
13 426
- 14 163. Spathling S, J dK, P H. Therapy of Lyme arthritis with ceftriaxon - histological proof of
15 spirochetes in the synovialis after ineffective therapy. *Zeitschrift für Rheumatologie*.
16 1992; 51(Suppl 2):40-41
- 17 164. Stanek G, Breier F, Menzinger G, Schaar B, Hafner M, Partsch H. Erythema migrans
18 and serodiagnosis by enzyme immunoassay and immunoblot with three borrelia
19 species. *Wiener Klinische Wochenschrift*. 1999; 111(22-23):951-956
- 20 165. Steere AC, Green J, Hutchinson GJ, Rahn DW, Pachner AR, Schoen RT et al.
21 Treatment of Lyme disease. *Zentralblatt für Bakteriologie, Mikrobiologie, und Hygiene*
22 *- Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology*. 1987;
23 263(3):352-356
- 24 166. Steere AC, Green J, Schoen RT, Taylor E, Hutchinson GJ, Rahn DW et al.
25 Successful parenteral penicillin therapy of established Lyme arthritis. *New England*
26 *Journal of Medicine*. 1985; 312(14):869-874
- 27 167. Steere AC, Hutchinson GJ, Rahn DW, Sigal LH, Craft JE, DeSanna ET et al.
28 Treatment of the early manifestations of Lyme disease. *Annals of Internal Medicine*.
29 1983; 99(1):22-26
- 30 168. Steere AC, Malawista SE, Newman JH, Spieler PN, Bartenhagen NH. Antibiotic
31 therapy in Lyme disease. *Annals of Internal Medicine*. 1980; 93(1 I):1-8
- 32 169. Steere AC, Pachner AR, Malawista SE. Neurologic abnormalities of Lyme disease:
33 successful treatment with high-dose intravenous penicillin. *Annals of Internal*
34 *Medicine*. 1983; 99(6):767-772
- 35 170. Steurer J. Month-long antibiotic therapy has no effect in persistent symptoms of Lyme
36 disease. *Praxis*. 2016; 105(12):723-724
- 37 171. Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L. Benefit of
38 intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme
39 disease. *International Journal of General Medicine*. 2011; 4:639-646
- 40 172. Stricker RB, Green CL, Savely VR, Chamallas SN, Johnson L. Safety of intravenous
41 antibiotic therapy in patients referred for treatment of neurologic Lyme disease.
42 *Minerva Medica*. 2010; 101(1):1-7
- 43 173. Strle F, Maraspin V, Lotric-Furlan S, Ruzic-Sabljić E, Cimperman J. Azithromycin and
44 doxycycline for treatment of borrelia culture-positive erythema migrans. *Infection*.
45 1996; 24(1):64-68

- 1 174. Strle F, Maraspin V, Pleterki-Rigler D, Lotric-Furlan S, Ruzic-Sabljić E, Jurca T et al.
2 Treatment of borrelial lymphocytoma. *Infection*. 1996; 24(1):80-84
- 3 175. Strle F, Pleterki-Rigler D, Stanek G, Pejovnik-Pustinek A, Ruzic E, Cimperman J.
4 Solitary borrelial lymphocytoma: report of 36 cases. *Infection*. 1992; 20(4):201-206
- 5 176. Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin
6 versus doxycycline for treatment of erythema migrans: clinical and microbiological
7 findings. *Infection*. 1993; 21(2):83-88
- 8 177. Stupica D, Lusa L, Cerar T, Ruzic-Sabljić E, Strle F. Comparison of post-lyme
9 borreliosis symptoms in erythema migrans patients with positive and negative borrelia
10 burgdorferi sensu lato skin culture. *Vector-Borne and Zoonotic Diseases*. 2011;
11 11(7):883-889
- 12 178. Stupica D, Lusa L, Maraspin V, Bogovic P, Vidmar D, O'Rourke M et al. Correlation of
13 culture positivity, PCR positivity, and burden of *Borrelia burgdorferi sensu lato* in skin
14 samples of erythema migrans patients with clinical findings. *PloS One*. 2015;
15 10(9):e0136600
- 16 179. Suarez-Magdalena O, Fernandez-Jorge B, Campo-Cerecedo F, Varela-Veiga A.
17 Atrophoderma of Pasini and Pierini associated with *Borrelia burgdorferi* treated with
18 doxycycline. *Piel*. 2017; 32(2):120-122
- 19 180. Thompson AD, Cohn KA, Shah SS, Lyons T, Welsh EJ, Hines EM et al. Treatment
20 complications in children with Lyme meningitis. *Pediatric Infectious Disease Journal*.
21 2012; 31(10):1032-1035
- 22 181. Thorstrand C, Belfrage E, Bennet R, Malmberg P, Eriksson M. Successful treatment
23 of neuroborreliosis with ten day regimens. *Pediatric Infectious Disease Journal*. 2002;
24 21(12):1142-1145
- 25 182. Thyresson N. The penicillin treatment of acrodermatitis atrophicans chronica
26 (Herxheimer). *Acta Dermato-Venereologica*. 1949; 29(6):572-621
- 27 183. Torbahn G, Hofmann H, Allert R, Freitag MH, Dersch R, Fingerle V et al. Efficacy and
28 safety of pharmacological agents in the treatment of erythema migrans in early Lyme
29 borreliosis-systematic review protocol. *Systems Review*. 2016; 5:73
- 30 184. Tory HO, Zurakowski D, Sundel RP. Outcomes of children treated for Lyme arthritis:
31 results of a large pediatric cohort. *Journal of Rheumatology*. 2010; 37(5):1049-1055
- 32 185. Tseng YJ, Demaria A, Goldmann DA, Mandl KD. Claims-based diagnostic patterns of
33 patients evaluated for lyme disease and given extended antibiotic therapy. *Vector-*
34 *Borne and Zoonotic Diseases*. 2017; 17(2):116-122
- 35 186. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J. Long-term results in
36 patients with Lyme arthritis following treatment with ceftriaxone. *Infection*. 1996;
37 24(1):98-102
- 38 187. Vazquez-Lopez ME, Diez-Morrondo C, Sanchez-Andrade A, Pego-Reigosa R, Diaz
39 P, Castro-Gago M. Articular manifestations in patients with Lyme disease.
40 *Reumatologia Clinica*. 2016; 12(6):327-330
- 41 188. Vazquez M, Sparrow SS, Shapiro ED. Long-term neuropsychologic and health
42 outcomes of children with facial nerve palsy attributable to Lyme disease. *Pediatrics*.
43 2003; 112(2):e93-97
- 44 189. Wahlberg P, Granlund H, Nyman D, Panelius J, Seppala I. Treatment of late Lyme
45 borreliosis. *Journal of Infection*. 1994; 29(3):255-261

- 1 190. Weber K, Neubert U, Thurmayer R. Antibiotic therapy in early erythema migrans
2 disease and related disorders. Zentralblatt fur Bakteriologie, Mikrobiologie, und
3 Hygiene - Series A, Medical Microbiology, Infectious Diseases, Virology,
4 Parasitology. 1987; 263(3):377-388
- 5 191. Weber K, Preac-Mursic V, Neubert U, Thurmayer R, Herzer P, Wilske B et al.
6 Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica
7 atrophicans. Annals of the New York Academy of Sciences. 1988; 539:324-345
- 8 192. Weissenbacher S, Ring J, Hofmann H. Gabapentin for the symptomatic treatment of
9 chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study.
10 Dermatology. 2005; 211(2):123-127
- 11 193. White B, Seaton RA, Evans TJ. Management of suspected lyme borreliosis:
12 experience from an outpatient parenteral antibiotic therapy service. QJM. 2013;
13 106(2):133-138
- 14 194. Zochling N, Mullegger RR, Schluepen EM, Soyer HP, Hodl S, Wienecke R et al.
15 Minocycline in early Lyme Borreliosis. Acta Dermatovenerologica Alpina, Panonica et
16 Adriatica. 1996; 5(3-4):163-168
- 17
- 18

1 Appendices

2 Appendix A: Review protocols

3 No separate review was undertaken to assess the effectiveness of treatment in people with
 4 persistent symptoms. People with persistent symptoms were included in the review
 5 population for the review question on the management of non-specific symptoms related to
 6 Lyme disease.

7 **Table 10: Review protocol for the management of non-specific symptoms**

8 Question number: 4.1

9 Relevant section of Scope: management

Field	Content
Review question	What is the most clinically and cost-effective treatment for seropositive people, who have non-specific symptoms that may be related to Lyme disease?
Type of review question	Intervention A review of health economic evidence related to the same review question was conducted in parallel with this review. For details, see the health economic review protocol for this NICE guideline.
Objective of the review	The review questions on the condition-specific management of Lyme disease aim to identify the most effective treatment in different clinical scenarios. The questions have been developed in a way to identify the evidence for all potential populations and scenarios, even if clinical presentations are more diverse. The population for this review consists of people with a seropositive test result for Lyme disease, who have non-specific symptoms that may be related to Lyme disease.
Eligibility criteria – population / disease / condition / issue / domain	People with Lyme disease determined by a diagnostic tests or clinical diagnosis who have non-specific symptoms that may be related to Lyme disease. This includes symptoms such as: <ul style="list-style-type: none"> • disturbed cognitive function, for example, memory loss • dizziness • fatigue • fever and sweats • headache • lymphadenopathy • myalgia and muscle stiffness • neck pain or stiffness • paraesthesia • photophobia
Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s)	Antimicrobials, including but not limited to: <ul style="list-style-type: none"> • Penicillins <ul style="list-style-type: none"> ○ Amoxicillin (oral, IV) ○ Ampicillin (oral, IV) ○ Benzylpenicillin sodium / Penicillin G (IV) <ul style="list-style-type: none"> - Including Augmentin (Amoxicillin and clavulanic acid; oral, IV) ○ Phenoxymethylpenicillin / Penicillin V (oral) • Tetracyclines

Field	Content
	<ul style="list-style-type: none"> ○ Doxycycline (oral) ○ Minocycline (oral) ● Cephalosporins <ul style="list-style-type: none"> ○ Cefotaxime (IV) ○ Ceftriaxone (IV) ○ Cefuroxime axetil (oral) ● Macrolides <ul style="list-style-type: none"> ○ Azithromycin (oral) ○ Clarithromycin (oral, IV) ● Fluoroquinolones <ul style="list-style-type: none"> ○ Ciprofloxacin (oral, IV) ○ Levofloxacin (oral, IV) ○ Moxifloxacin (oral, IV) ○ Nalidixic acid (oral) ○ Norfloxacin (oral) ○ Ofloxacin (oral, IV) ● Rifampicin (oral, IV)
Eligibility criteria – comparator(s) / control or reference (gold) standard	<ul style="list-style-type: none"> ● Antimicrobial agents compared with each other <ul style="list-style-type: none"> ○ If data are available, consider: <ul style="list-style-type: none"> - Type of antimicrobial agent (within class or between class) - Route of administration - Duration of treatment: 1 month versus longer ● Monotherapy versus polytherapy (any combination) ● Antimicrobial agents compared to no treatment / placebo
Outcomes and prioritisation	<p>Critical:</p> <ol style="list-style-type: none"> 1. Quality of life (any validated measure) 2. Cure (resolution of symptoms) 3. Reduction of clinical symptoms 4. Symptom relapse <p>Important:</p> <ol style="list-style-type: none"> 5. Adverse events
Eligibility criteria – study design	<ul style="list-style-type: none"> ● RCTs ● Cohort studies (if no RCT evidence is found)
Other inclusion exclusion criteria	<p>Date limits for search: none Language: English only Setting: all settings in which NHS care is provided or commissioned The following interventions will not be considered for inclusion:</p> <ul style="list-style-type: none"> ● Metronidazole ● Trimethoprim
Proposed sensitivity / subgroup analysis, or meta-regression	<p>The following groups will be considered separately if data are available (strata):</p> <ul style="list-style-type: none"> ● Children (under 12 years); young people and adults (12 years and over) ● Onset of specific symptoms less than 6 weeks; 6 weeks to 6 months; over 6 months <p>Subgroups (to be investigated if heterogeneity is identified):</p> <ul style="list-style-type: none"> ● Pregnant women ● People who are immunocompromised ● People in whom a previous course of antimicrobial treatment has

Field	Content
	failed
Selection process – duplicate screening / selection / analysis	Studies will be sifted by title and abstract. Potentially significant publications obtained in full text will then be assessed against the inclusion criteria specified in this protocol.
Data management (software)	Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5). GRADEpro will be used to assess the quality of evidence for each outcome Bibliographies, citations, study sifting and reference management will be managed using EndNote. Data extractions will be performed using EviBase, a platform designed and maintained by the National Guideline Centre (NGC)
Information sources – databases and dates	Clinical searches Medline, Embase, The Cochrane Library all years Health economic searches Medline, Embase, NHS Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA) all years
Identify if an update	Not applicable
Author contacts	https://www.nice.org.uk/guidance/indevelopment/gid-ng10007
Highlight if amendment to previous protocol	For details, please see section 4.5 of Developing NICE guidelines: the manual.
Search strategy – for one database	For details, please see appendix B
Data collection process – forms / duplicate	A standardised evidence table format will be used, and published as appendix D of the evidence report.
Data items – define all variables to be collected	For details, please see evidence tables in appendix D (clinical evidence tables) or H (health economic evidence tables).
Methods for assessing bias at outcome / study level	Standard study checklists were used to appraise individual studies critically. For details, please see section 6.2 of Developing NICE guidelines: the manual The risk of bias across all available evidence will be evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group http://www.gradeworkinggroup.org/
Criteria for quantitative synthesis	For details, please see section 6.4 of Developing NICE guidelines: the manual. Meta-analysis will be conducted wherever possible (that is, where similar studies can be combined) In the absence of clinically established MIDs, standard MIDs for dichotomous (25% risk reduction or risk increase) and continuous outcomes (+/-0.5 standard deviation) will be used If heterogeneity is found, the influence of subgroups will be examined
Methods for quantitative analysis – combining studies and exploring (in)consistency	For details, please see the separate Methods report for this guideline.
Meta-bias assessment – publication bias, selective reporting bias	For details, please see section 6.2 of Developing NICE guidelines: the manual.
Confidence in cumulative	For details, please see sections 6.4 and 9.1 of Developing NICE

Field	Content
evidence	guidelines: the manual.
Rationale / context – what is known	For details, please see the introduction to the evidence review.
Describe contributions of authors and guarantor	A multidisciplinary committee developed the evidence review. The committee was convened by the NGC and chaired by Saul Faust in line with section 3 of Developing NICE guidelines: the manual. Staff from the NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details, please see Developing NICE guidelines: the manual.
Sources of funding / support	The NGC is funded by NICE and hosted by the Royal College of Physicians.
Name of sponsor	The NGC is funded by NICE and hosted by the Royal College of Physicians.
Roles of sponsor	NICE funds the NGC to develop guidelines for those working in the NHS, public health and social care in England.
PROSPERO registration number	Not registered

1

Table 11: Health economic review protocol

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2001, abstract-only studies and studies from non-OECD countries or the US will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).¹¹⁸</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’, then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. • If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’, then it will usually be excluded from the guideline. If it is excluded, then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or

both, then there is discretion over whether it should be included.

Where there is discretion

The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to exclude the remaining studies selectively. All studies excluded based on applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the US will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2001 or later but that depend on unit costs and resource data entirely or predominantly before 2001 will be rated as ‘Not applicable’.
- Studies published before 2001 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

1

2

Appendix B: Literature search strategies

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2017
<https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869>

For more detailed information, please see the Methodology Review.

B.1 Clinical search literature search strategy

The search for this review was constructed using population terms. An excluded studies filter was applied where appropriate.

Table 12: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 03 July 2017	Exclusions
Embase (OVID)	1974 – 03 July 2017	Exclusions
The Cochrane Library (Wiley)	Cochrane Reviews to 2017 Issue 7 of 12 CENTRAL to 2017 Issue 6 of 12 DARE, and NHSEED to 2015 Issue 2 of 4 HTA to 2016 Issue 4 of 4	None

Medline (Ovid) search terms

1.	exp Borrelia Infections/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodid or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter/
13.	editorial/
14.	news/
15.	exp historical article/
16.	Anecdotes as Topic/
17.	comment/
18.	(letter or comment*).ti.
19.	or/12-18
20.	randomized controlled trial/ or random*.ti,ab.
21.	19 not 20

22.	animals/ not humans/
23.	exp Animals, Laboratory/
24.	exp Animal Experimentation/
25.	exp Models, Animal/
26.	exp Rodentia/
27.	(rat or rats or mouse or mice).ti.
28.	or/21-27
29.	11 not 28
30.	limit 29 to English language

1

Embase (Ovid) search terms

1.	exp Borrelia Infection/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter.pt. or letter/
13.	note.pt.
14.	editorial.pt.
15.	(letter or comment*).ti.
16.	or/12-15
17.	randomized controlled trial/ or random*.ti,ab.
18.	16 not 17
19.	animal/ not human/
20.	Nonhuman/
21.	exp Animal Experiment/
22.	exp Experimental animal/
23.	Animal model/
24.	exp Rodent/
25.	(rat or rats or mouse or mice).ti.
26.	or/18-25
27.	11 not 26
28.	limit 27 to English language

2

Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Borrelia Infections] explode all trees
#2.	MeSH descriptor: [Lyme Disease] explode all trees
#3.	MeSH descriptor: [Erythema Chronicum Migrans] explode all trees
#4.	(erythema near/3 migrans):ti,ab

#5.	lyme*:ti,ab
#6.	(tick* near/2 (bite* or bitten or biting or borne)):ti,ab
#7.	acrodermatitis chronica atrophicans:ti,ab
#8.	MeSH descriptor: [Ixodidae] explode all trees
#9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or ixodid or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti):ti,ab
#10.	(granulocytic anaplasmosis or babesia or babesiosis):ti,ab
#11.	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10

1 B.2 Health Economics literature search strategy

2 Health economic evidence was identified by conducting a broad search relating to Lyme
3 disease population in NHS Economic Evaluation Database (NHS EED – this ceased to be
4 updated after March 2015) and the Health Technology Assessment database (HTA) with no
5 date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and
6 Dissemination (CRD). Additional searches were run on Medline and Embase for health
7 economics, economic modelling and quality of life studies.

8 **Table 13: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline	1946 – 03 July 2017	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Embase	1974 – 03 July 2017	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 03 July 2017 NHSEED - Inception to March 2015	None

9 **Medline (Ovid) search terms**

1.	exp Borrelia Infections/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodid or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter/

13.	editorial/
14.	news/
15.	exp historical article/
16.	Anecdotes as Topic/
17.	comment/
18.	(letter or comment*).ti.
19.	or/12-18
20.	randomized controlled trial/ or random*.ti,ab.
21.	19 not 20
22.	animals/ not humans/
23.	exp Animals, Laboratory/
24.	exp Animal Experimentation/
25.	exp Models, Animal/
26.	exp Rodentia/
27.	(rat or rats or mouse or mice).ti.
28.	or/21-27
29.	11 not 28
30.	limit 29 to English language
31.	Economics/
32.	Value of life/
33.	exp "Costs and Cost Analysis"/
34.	exp Economics, Hospital/
35.	exp Economics, Medical/
36.	Economics, Nursing/
37.	Economics, Pharmaceutical/
38.	exp "Fees and Charges"/
39.	exp Budgets/
40.	budget*.ti,ab.
41.	cost*.ti.
42.	(economic* or pharmaco?economic*).ti.
43.	(price* or pricing*).ti,ab.
44.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
45.	(financ* or fee or fees).ti,ab.
46.	(value adj2 (money or monetary)).ti,ab.
47.	or/31-46
48.	exp models, economic/
49.	*Models, Theoretical/
50.	*Models, Organizational/
51.	markov chains/
52.	monte carlo method/

53.	exp Decision Theory/
54.	(markov* or monte carlo).ti,ab.
55.	econom* model*.ti,ab.
56.	(decision* adj2 (tree* or analy* or model*)).ti,ab.
57.	or/48-56
58.	quality-adjusted life years/
59.	sickness impact profile/
60.	(quality adj2 (wellbeing or well being)).ti,ab.
61.	sickness impact profile.ti,ab.
62.	disability adjusted life.ti,ab.
63.	(qal* or qtime* or qwb* or daly*).ti,ab.
64.	(euroqol* or eq5d* or eq 5*).ti,ab.
65.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
66.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
67.	(hui or hui1 or hui2 or hui3).ti,ab.
68.	(health* year* equivalent* or hye or hyes).ti,ab.
69.	discrete choice*.ti,ab.
70.	rosser.ti,ab.
71.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
72.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
73.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
74.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
75.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
76.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
77.	or/58-76
78.	30 and 47
79.	30 and 57
80.	30 and 77

1

Embase (Ovid) search terms

1.	exp Borrelia Infection/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.

11.	or/1-10
12.	letter.pt. or letter/
13.	note.pt.
14.	editorial.pt.
15.	Case report/ or Case study/
16.	(letter or comment*).ti.
17.	or/12-16
18.	randomized controlled trial/ or random*.ti,ab.
19.	17 not 18
20.	animal/ not human/
21.	Nonhuman/
22.	exp Animal Experiment/
23.	exp Experimental animal/
24.	Animal model/
25.	exp Rodent/
26.	(rat or rats or mouse or mice).ti.
27.	or/19-26
28.	11 not 27
29.	limit 28 to English language
30.	health economics/
31.	exp economic evaluation/
32.	exp health care cost/
33.	exp fee/
34.	budget/
35.	funding/
36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/30-42
44.	statistical model/
45.	exp economic aspect/
46.	44 and 45
47.	*theoretical model/
48.	*nonbiological model/
49.	stochastic model/
50.	decision theory/

51.	decision tree/
52.	monte carlo method/
53.	(markov* or monte carlo).ti,ab.
54.	econom* model*.ti,ab.
55.	(decision* adj2 (tree* or analy* or model*)).ti,ab.
56.	or/46-55
57.	quality adjusted life year/
58.	"quality of life index"/
59.	short form 12/ or short form 20/ or short form 36/ or short form 8/
60.	sickness impact profile/
61.	(quality adj2 (wellbeing or well being)).ti,ab.
62.	sickness impact profile.ti,ab.
63.	disability adjusted life.ti,ab.
64.	(qal* or qtime* or qwb* or daly*).ti,ab.
65.	(euroqol* or eq5d* or eq 5*).ti,ab.
66.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
67.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
68.	(hui or hui1 or hui2 or hui3).ti,ab.
69.	(health* year* equivalent* or hye or hyes).ti,ab.
70.	discrete choice*.ti,ab.
71.	rosser.ti,ab.
72.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
73.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
74.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
75.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
76.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
77.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
78.	or/57-77
79.	29 and 43
80.	29 and 56
81.	29 and 78

1

NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Borrelia Infections EXPLODE ALL TREES IN NHSEED,HTA
#2.	MeSH DESCRIPTOR Erythema Chronicum Migrans EXPLODE ALL TREES IN NHSEED,HTA
#3.	((erythema adj3 migrans)) IN NHSEED, HTA
#4.	(lyme*) IN NHSEED, HTA
#5.	((tick* adj2 (bite* or bitten or biting or borne))) IN NHSEED, HTA
#6.	(acrodermatitis chronica atrophicans) IN NHSEED, HTA
#7.	MeSH DESCRIPTOR Ixodidae EXPLODE ALL TREES IN NHSEED,HTA
#8.	((borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti)) IN NHSEED, HTA
#9.	((granulocytic anaplasmosis or babesia or babesiosis)) IN NHSEED, HTA
#10.	MeSH DESCRIPTOR Lyme Disease EXPLODE ALL TREES IN NHSEED,HTA


#11.	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
------	---

1
2

1

Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of the management of specific clinical scenarios for Lyme disease



2

Appendix D: Clinical evidence tables

Study	Klempner 2001 ⁸⁰
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=129)
Countries and setting	Conducted in USA; Setting: Dual-centre
Line of therapy	first line
Duration of study	Follow up (post intervention): 180 days
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Clinical diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	18 years or older, history of acute Lyme disease acquired in the US, at least 1 of the following: history of single or multiple EM, early neurologic or cardiac symptoms attributed to Lyme disease, radiculoneuropathy, or Lyme arthritis
Exclusion criteria	Hypersensitivity to the study medications, previous parenteral antibiotic treatment for 60 days or more for their current symptoms, active inflammatory synovitis, coexisting condition that could have accounted for their symptoms, unable to discontinue medications that could interfere with the evaluation of their response to the treatment regimen
Recruitment or selection of people	Not reported
Age, gender and family origin	Age - Mean (SD): Antibiotic group: 54 years (14); placebo group: 53 years (13). Gender (M:F): Define. Family origin: 92% white Previous course of antibiotic treatment: 42 people (33%) received intravenous antibiotics, 87 people (67%) received oral antibiotics; mean number of previous antibiotic courses: 2.7 (SD 1.3)
Further population details	1. Immunocompromised people: Not applicable 2. Pregnant women: Not applicable
Indirectness of population	Serious indirectness: People were eligible if they had any specific symptoms (such as EM, neurological symptoms)
Interventions	(n=64) Intervention 1: Polytherapy. 2 g ceftriaxone per day intravenous for 30 days followed by 100 mg doxycycline orally twice per day for 60 days. Duration 90 days. Concurrent medication/care: Not reported (n=65) Intervention 2: Placebo. Dextrose solution intravenous for 30 days followed by oral capsules for 90

Study	Klempner 2001⁸⁰
	days. Duration 90 days. Concurrent medication/care: Not reported
Funding	Equipment / drugs provided by industry
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: POLYTHERAPY versus PLACEBO	
<p>Protocol outcome 1: Quality of life</p> <p>- Actual outcome: Improvement in SF-36 total score at 180 days; Group 1: 23/57, Group 2: 21/58</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 7; Group 2 Number missing: 7</p> <p>- Actual outcome: Improvement in SF-36 physical component at 180 days; Group 1: 20/57, Group 2: 15/58</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 7; Group 2 Number missing: 7</p> <p>- Actual outcome: Improvement in SF-36 mental component at 180 days; Group 1: 19/57, Group 2: 22/58</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 7; Group 2 Number missing: 7</p>	
<p>Protocol outcome 2: Adverse events</p> <p>- Actual outcome: Adverse events at 90 days; Group 1: 16/64, Group 2: 11/65</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Cure (resolution of symptoms); Reduction of symptoms; Symptom relapse

Study	Krupp 2003 ⁸⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=56)
Countries and setting	Conducted in USA; Setting: Multi-centre
Line of therapy	first line
Duration of study	Follow up (post intervention): 6 months
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Clinical diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Aged 18-70 years, history of physician-documented EM or CDC-defined late manifestation of Lyme disease confirmed by positive ELISA and WB serology, completion (6 months before study entry) of standard antibiotic treatment for Lyme disease as defined by at least a 3-week course of oral antibiotic therapy or 3 weeks of IV ceftriaxone, current severe fatigue defined by an elevated score (4 or more) on a modified version of the Fatigue Severity Scale
Exclusion criteria	Mental disorder, medical disorder that confounded the assessment of severe fatigue or cognitive loss, cephalosporin allergy, severe psychiatric disorders
Recruitment or selection of people	Not reported
Age, gender and family origin	Age - Mean (SD): Ceftriaxone group: 48.0 years (11.8); placebo group: 47.0 years (9.7). Gender (M:F): 37:19. Family origin: 52 white
Further population details	1. Immunocompromised people: Not stated / Unclear 2. Pregnant women: Not stated / Unclear
Indirectness of population	Serious indirectness: People previously had either EM or late Lyme manifestations
Interventions	(n=28) Intervention 1: Antibiotics - Ceftriaxone. 2 g per day, intravenous. Duration 28 days. Concurrent medication/care: Not reported (n=27) Intervention 2: Placebo. Placebo intravenous. Duration 28 days. Concurrent medication/care: Not reported
Funding	Academic or government funding
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CEFTRIAXONE versus PLACEBO	
Protocol outcome 1: Reduction of symptoms at Define - Actual outcome: Improvement in fatigue at 6 months; Group 1: 18/28, Group 2: 5/27	

Study	Krupp 2003 ⁸⁵
	<p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>- Actual outcome: FSS-11 score at 6 months; Group 1: mean 4.4 (SD 1.5); n=26, Group 2: mean 5.5 (SD 1.3); n=22; Fatigue Severity Scale 0-77 Top equals High is poor outcome</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2; Group 2 Number missing: 5</p> <p>- Actual outcome: Change in FSS-11 score from baseline at 6 months; Group 1: mean -1.3 (SD 1.4); n=26, Group 2: mean -0.5 (SD 0.93); n=22; Fatigue Severity Scale 0-77 Top equals High is poor outcome</p> <p>Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 2; Group 2 Number missing: 5</p> <p>- Actual outcome: Improvement in cognitive measure at 6 months; Group 1: 2/26, Group 2: 2/22</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 3; Group 2 Number missing: 5</p> <p>- Actual outcome: A-A score at 6 months; Group 1: mean 3.8 Seconds (SD 1.7); n=26; Group 2: mean 3.4 Seconds (SD 1); n=22</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 3; Group 2 Number missing: 5</p> <p>- Actual outcome: Change in A-A test score from baseline at 6 months; Group 1: mean -0.3 Seconds (SD 1); n=25; Group 2: mean -0.5 Seconds (SD 0.8); n=22</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 3; Group 2 Number missing: 5</p>
Protocol outcomes not reported by the study	Quality of life; Cure (resolution of symptoms); Symptom relapse; Adverse events

Study	PLEASE trial: Berende 2016 ¹⁵
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=281)
Countries and setting	Conducted in Netherlands; Setting: Single centre
Line of therapy	first line
Duration of study	Intervention time: 12 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Clinical diagnosis
Stratum	Overall

Study	PLEASE trial: Berende 2016 ¹⁵
Subgroup analysis within study	Not applicable
Inclusion criteria	Persistent symptoms attributed to Lyme disease temporarily related to an EM or an otherwise proven case of symptomatic Lyme disease or accompanied by <i>B burgdorferi</i> IgM or IgG antibodies
Exclusion criteria	allergy or intolerance to study drugs or ceftriaxone, more than 5 days of antimicrobial therapy with activity against <i>B burgdorferi</i> within previous 4 weeks, presumed diagnosis of neuroborreliosis, known diagnosis of HIV-seropositivity or other immune disorders, positive syphilis serology, liver disease, enrolled in other trials, previously randomised into this study, comorbidity that could account for symptoms of the subject
Recruitment or selection of people	Not reported
Age, gender and family origin	Age - Mean (SD): Doxycycline group: 48.1 years (12.8); clarithromycin group: 48.2 years (13.0); placebo group: 50.0 years (9.7). Gender (M:F): 151:129. Family origin: Doxycycline group: 98% white; clarithromycin group: 96% white; placebo group: 98% white
Further population details	1. Immunocompromised people: Not applicable 2. Pregnant women: Not applicable
Indirectness of population	No indirectness
Interventions	<p>(n=86) Intervention 1: Antibiotics - Doxycycline. 100 mg oral twice daily. Duration 12 weeks. Concurrent medication/care: Open-label intravenous ceftriaxone (2000 mg daily) for 14 days prior to study intervention. Placebo combined with study intervention.</p> <p>(n=96) Intervention 2: Antibiotics - Clarithromycin. 500 mg clarithromycin orally twice daily plus 200 mg hydroxychloroquine orally twice daily. Duration 12 weeks. Concurrent medication/care: Open-label intravenous ceftriaxone (2000 mg daily) for 14 days prior to study intervention.</p> <p>(n=98) Intervention 3: Placebo. Two different placebo capsules orally twice daily. Duration 12 weeks. Concurrent medication/care: Open-label intravenous ceftriaxone (2000 mg daily) for 14 days prior to study intervention.</p>
Funding	Academic or government funding (Netherlands Health Research grant)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DOXYCYCLINE versus CLARITHROMYCIN	
<p>Protocol outcome 1: Quality of life</p> <p>- Actual outcome for Adults: SF-36 physical component summary score at 14 weeks; 35.0 (95% CI 33.5 to 36.5) versus 35.6 (95% CI 34.2 to 37.1)</p> <p>Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcome 2: Adverse events	

Study	PLEASE trial: Berende 2016 ¹⁵
<p>- Actual outcome for Adults: Any drug-related adverse event at 14 weeks; Group 1: 42/86, Group 2: 42/96 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>- Actual outcome for Adults: Discontinued treatment due to adverse events at 14 weeks; Group 1: 3/86, Group 2: 7/96 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: DOXYCYCLINE versus PLACEBO</p>	
<p>Protocol outcome 1: Quality of life</p> <p>- Actual outcome for Adults: SF-36 physical component summary score at 14 weeks; 35.0 (95% CI 33.5 to 36.5) versus 34.8 (95% CI 33.4 to 36.2) Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 2: Adverse events</p> <p>- Actual outcome for Adults: Any drug-related adverse event at 14 weeks; Group 1: 42/86, Group 2: 34/98 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>- Actual outcome for Adults: Discontinued treatment due to adverse events at 14 weeks; Group 1: 3/86, Group 2: 4/98 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: CLARITHROMYCIN versus PLACEBO</p>	
<p>Protocol outcome 1: Quality of life at Define</p> <p>- Actual outcome for Adults: SF-36 physical component summary score at 14 weeks; 35.6 (95% CI 34.2 to 37.1) versus 34.8 (95% CI 33.4 to 36.2) Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
<p>Protocol outcome 2: Adverse events at Define</p> <p>- Actual outcome for Adults: Any drug-related adverse event at 14 weeks; Group 1: 42/96, Group 2: 34/98 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover</p>	

Study	PLEASE trial: Berende 2016 ¹⁵
- Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0 - Actual outcome for Adults: Discontinued treatment due to adverse events at 14 weeks; Group 1: 7/96, Group 2: 4/98 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low; Indirectness of outcome: No indirectness; Group 1 Number missing: 0; Group 2 Number missing: 0	
Protocol outcomes not reported by the study	Cure (resolution of symptoms); Reduction of symptoms; Symptom relapse

1 Appendix E: Forest plots

2 E.1 Ceftriaxone (IV) followed by doxycycline (PO) versus 3 placebo

4 E.1.1 Persistent Lyme disease symptoms

Figure 2: Improvement in quality of life




Figure 3: Improvement in SF-36 (physical component)




Figure 4: Improvement in SF-36 (mental component)





Figure 5: Adverse events



1 E.2 Ceftriaxone (IV) versus placebo

2 E.2.1 Persistent Lyme disease symptoms

Figure 6: Improvement in fatigue




Figure 7: FS-11 score (final values)




Figure 8: Change in FSS-11 score from baseline




Figure 9: Improvement in cognitive measure




Figure 10: A-A score (final values)





Figure 11: Change in A-A score from baseline



1 E.3 Ceftriaxone (IV) followed by doxycycline (PO) versus 2 ceftriaxone (IV) followed by clarithromycin (PO) plus 3 hydroxychloroquine

4 E.3.1 Persistent Lyme disease symptoms

Figure 12: SF-36 (physical component – final values)




Figure 13: Adverse events





Figure 14: Discontinued treatment due to adverse events



5 E.4 Ceftriaxone (IV) followed by doxycycline (PO) versus 6 ceftriaxone (IV)

7 E.4.1 Persistent Lyme disease symptoms

Figure 15: SF-36 (physical component – final values)




Figure 16: Adverse events





Figure 17: Discontinued treatment due to adverse events



1 **E.5 Ceftriaxone (IV) followed by clarithromycin (PO) plus**
2 **hydroxychloroquine versus ceftriaxone (IV)**

3 **E.5.1 Persistent Lyme disease symptoms**

Figure 18: SF-36 (physical component – final values)




Figure 19: Adverse events





Figure 20: Discontinued treatment due to adverse events



4

Appendix F: GRADE tables

Table 14: Clinical evidence profile: Ceftriaxone (IV) followed by doxycycline (PO) versus placebo

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ceftriaxone plus doxycycline	Placebo	Relative (95% CI)	Absolute		
Improvement in quality of life at 180 days												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	23/57 (40.4%)	21/58 (36.2%)	RR 1.11 (0.7 to 1.77)	40 more per 1000 (from 109 fewer to 279 more)	⊕○○○ VERY LOW	CRITICAL
Improvement in SF-36 (physical component) at 180 days; 0-100, higher values are beneficial												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	20/57 (35.1%)	15/58 (25.9%)	RR 1.36 (0.77 to 2.38)	93 more per 1000 (from 59 fewer to 357 more)	⊕⊕○○ LOW	CRITICAL
Improvement in SF-36 (mental component) at 180 days; 0-100, higher values are beneficial												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	very serious ²	none	19/57 (33.3%)	22/58 (37.9%)	RR 0.88 (0.54 to 1.44)	46 fewer per 1000 (from 174 fewer to 167 more)	⊕○○○ VERY LOW	CRITICAL
Adverse events at 90 days												

1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	16/64 (25%)	11/65 (16.9%)	RR 1.48 (0.74 to 2.93)	81 more per 1000 (from 44 fewer to 327 more)	⊕⊕⊕⊕ LOW	IMPORTANT
---	-------------------	-------------------------	--------------------------	-------------------------	---------------------------	------	-------------	---------------	------------------------	--	----------	-----------

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

Table 15: Clinical evidence profile: Ceftriaxone (IV) versus placebo

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ceftriaxone	Placebo	Relative (95% CI)	Absolute		
Improvement in fatigue at 6 months												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	18/28 (64.3%)	5/27 (18.5%)	RR 3.47 (1.5 to 8.02)	457 more per 1000 (from 93 more to 1000 more)	⊕⊕⊕⊕ HIGH	CRITICAL
FSS-11 score at 6 months; 0-77, lower values are beneficial												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	26	22	Not applicable	MD 1.1 lower (1.89 to 0.31 lower)	⊕⊕⊕⊕ LOW	CRITICAL
Change in FSS-11 score from baseline at 6 months; 0-77, lower values are beneficial												
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	26	22	Not applicable	MD 0.8 lower (1.46 to 0.14 lower)	⊕⊕⊕⊕ LOW	CRITICAL
Improvement in cognitive measure at 6 months												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ²	none	2/26 (7.7%)	2/22 (9.1%)	RR 0.85 (0.13 to 5.52)	14 fewer per 1000 (from 79 fewer to 411 more)	⊕⊕⊕⊕ LOW	CRITICAL
A-A score at 6 months; cognitive processing speed measured in milliseconds, lower values are beneficial												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ²	none	26	22	Not applicable	MD 0.4 higher (0.38 to 0.42 higher)	⊕⊕⊕⊕ LOW	CRITICAL

	trials	risk of bias	inconsistency	indirectness					applicable	lower to 1.18 higher)	MODERATE	
Change in A-A score from baseline at 6 months; cognitive processing speed measured in milliseconds, lower values are beneficial												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ²	none	25	22	Not applicable	MD 0.2 higher (0.32 lower to 0.72 higher)	⊕⊕⊕O MODERATE	CRITICAL

¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

Table 16: Clinical evidence profile: Ceftriaxone (IV) followed by doxycycline (PO) versus ceftriaxone (IV) followed by clarithromycin (PO) plus hydroxychloroquine

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ceftriaxone plus doxycycline	Ceftriaxone plus clarithromycin plus hydroxychloroquine	Relative (95% CI)	Absolute		
SF-36 (physical component) at 14 weeks; 15-61 (norm-based T-score), general population score 50 (SD 10), higher values are beneficial												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious ¹	serious imprecision ²	none	86	96	Not applicable	MD 0.6 lower (2.62 lower to 1.42 higher)	⊕⊕OO LOW	CRITICAL
Adverse events at 14 weeks												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious ¹	Serious ²	none	42/86 (48.8%)	42/96 (43.8%)	RR 1.12 (0.82 to 1.53)	53 more per 1000 (from 79 fewer to 232 more)	⊕⊕OO LOW	IMPORTANT
Discontinued treatment due to adverse events at 14 weeks												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious ¹	very serious ²	none	3/86 (3.5%)	7/96 (7.3%)	RR 0.48 (0.13 to 1.79)	38 fewer per 1000 (from 63 fewer to 58 more)	⊕OOO VERY LOW	IMPORTANT

¹ People in the clarithromycin group also received hydroxychloroquine
² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

Table 17: Clinical evidence profile: Ceftriaxone (IV) followed by doxycycline (PO) versus ceftriaxone (IV)

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ceftriaxone plus doxycycline	Ceftriaxone	Relative (95% CI)	Absolute		
SF-36 (physical component) at 14 weeks; 15-61 (norm-based T-score), general population score 50 (SD 10), higher values are beneficial												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious imprecision ¹	none	86	98	Not applicable	MD 0.2 higher (1.82 lower to 2.22 higher)	⊕⊕⊕⊕ MODERATE	CRITICAL
Adverse events at 14 weeks												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ¹	none	42/86 (48.8%)	34/98 (34.7%)	RR 1.41 (0.99 to 1.99)	142 more per 1000 (from 3 fewer to 343 more)	⊕⊕⊕⊕ MODERATE	IMPORTANT
Discontinued treatment due to adverse events at 14 weeks												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious ¹	none	3/86 (3.5%)	4/98 (4.1%)	RR 0.85 (0.2 to 3.71)	6 fewer per 1000 (from 33 fewer to 111 more)	⊕⊕⊕⊕ LOW	IMPORTANT

¹ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

Table 18: Clinical evidence profile: Ceftriaxone (IV) followed by clarithromycin (PO) plus hydroxychloroquine versus ceftriaxone (IV)

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ceftriaxone plus clarithromycin plus hydroxychloroquine	Ceftriaxone	Relative (95% CI)	Absolute		

SF-36 (physical component) at 14 weeks; 15-61 (norm-based T-score), general population score 50 (SD 10), higher values are beneficial												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious ¹	serious imprecision ²	none	96	98	Not applicable	MD 0.8 higher (1.15 lower to 2.75 higher)	⊕⊕○○ LOW	CRITICAL
Adverse events at 14 weeks												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious ¹	Serious ²	none	42/96 (43.8%)	34/98 (34.7%)	RR 1.26 (0.89 to 1.8)	90 more per 1000 (from 38 fewer to 278 more)	⊕⊕○○ LOW	IMPORTANT
Discontinued treatment due to adverse events at 14 weeks												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious ¹	very serious ²	none	7/96 (7.3%)	4/98 (4.1%)	RR 1.79 (0.54 to 5.91)	32 more per 1000 (from 19 fewer to 200 more)	⊕○○○ VERY LOW	IMPORTANT


¹ People in the clarithromycin group also received hydroxychloroquine

² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

1
2

Appendix G: Health economic evidence selection

Figure 21: Flow chart of economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language

3

1 **Appendix H: Health economic evidence**
2 **tables**

3 None.

1 Appendix I: Excluded studies

2 I.1 Excluded clinical studies

3 **Table 19: Studies excluded from the clinical management reviews**

Reference	Reason for exclusion
Aberer 2006 ¹	Excluded due to an incorrect intervention
Abrutyn 1989 ²	Excluded due to an incorrect study design
Agger 1992 ³	Excluded due to an incorrect study design
Agus 1995 ⁴	Excluded due to an incorrect study design
Agwuh 2006 ⁵	Excluded due to an incorrect study design
Ahmed 2005 ⁶	Excluded due to an incorrect study design
Ahmed 2013 ⁷	Excluded due to an incorrect study design
Alarcon 1994 ⁸	Excluded due to an incorrect study design
Andiman 1986 ⁹	Excluded due to an incorrect study design
Anonymous 1991 ¹⁰	Excluded due to an incorrect study design
Arvikar 2015 ¹¹	Excluded due to an incorrect study design
Auwaerter 2004 ¹²	Excluded due to an incorrect study design
Bennet 2003 ¹³	Excluded due to an incorrect study design
Berende 2014 ¹⁴	Excluded due to an incorrect study design
Berger 1988 ¹⁷	Excluded due to an incorrect study design
Berger 1986 ¹⁶	Excluded due to an incorrect study design
Bernardino 2009 ¹⁸	Excluded due to an incorrect study design
Bhate 2011 ¹⁹	Excluded due to an incorrect study design
Bjark 2016 ²⁰	Not available
Borg 2005 ²³	Excluded due to an incorrect study design
Bratton 2008 ²⁴	Excluded due to an incorrect study design
Bremell 2014 ²⁵	Excluded due to an incorrect study design
British Infection Association 2011 ²⁶	Excluded due to an incorrect study design
Butler 1978 ²⁷	Excluded due to an incorrect population
Cadavid 2016 ²⁸	Excluded due to an incorrect study design
Canadian Paediatric Society 1992 ²⁹	Excluded due to an incorrect study design
Chen 1999 ³¹	Excluded due to an incorrect outcome
Choo-Kang 2010 ³²	Excluded due to an incorrect study design
Christian 1992 ³³	Excluded due to an incorrect study design
Cimmino 1992 ³⁵	Excluded due to an incorrect study design
Cimmino 1997 ³⁴	Excluded due to an incorrect study design
Cimperman 1999 ³⁶	Excluded due to an incorrect study design
Coblyn 1981 ³⁷	Excluded due to an incorrect study design
Committee on Infectious Diseases 1991 ³⁹	Excluded due to an incorrect study design
Cuisset 2008 ⁴⁰	Excluded due to an incorrect study design
Dattwyler 1996 ⁴²	Excluded due to an incorrect comparison
Dattwyler 1987 ⁴³	Excluded due to an incorrect study design
Dattwyler 1988 ⁴⁴	Excluded due to an incorrect population
Dattwyler 2005 ⁴⁵	Excluded due to an incorrect population
Dersch 2015 ⁴⁷	Excluded due to an incorrect study design

Reference	Reason for exclusion
Dersch 2016 ⁵⁰	Excluded due to an incorrect study design
Dersch 2014 ⁴⁸	Excluded due to an incorrect study design
Dersch 2017 ⁴⁹	Not available
Dhoot 2011 ⁵¹	Excluded due to an incorrect study design
Dinser 2005 ⁵²	Excluded due to an incorrect study design
Dotevall 1988 ⁵³	Excluded due to an incorrect study design
Eliassen 2017 ⁵⁴	Excluded due to an incorrect study design
Eliassen 2017 ⁵⁵	Excluded due to an incorrect intervention
Eppes 2003 ⁵⁶	Excluded due to an incorrect study design
Esposito 2013 ⁵⁷	Excluded due to an incorrect study design
Fallon 1999 ⁵⁹	Excluded due to an incorrect intervention
Fallon 2008 ⁵⁸	Excluded due to an incorrect outcome
Galev 2005 ⁶⁰	Excluded due to an incorrect study design
Garkowski 2017 ⁶¹	Systematic review
Gasser 1996 ⁶³	Excluded due to an incorrect not available
Gasser 1995 ⁶⁴	Excluded due to an incorrect study design
Gasser 1995 ⁶²	Excluded due to an incorrect study design
Gerber 1996 ⁶⁵	Excluded due to an incorrect intervention
Gillies 2015 ⁶⁶	Excluded due to an incorrect study design
Goodwin 1990 ⁶⁷	Excluded due to an incorrect study design
Hansen 1992 ⁶⁸	Excluded due to an incorrect intervention
Hassler 1990 ⁶⁹	Excluded due to an incorrect population
Horton 2017 ⁷⁰	Conference abstract
Hu 2001 ⁷¹	Excluded due to an incorrect study design
Inboriboon 2010 ⁷²	Excluded due to an incorrect study design
Kaplan 2003 ⁷³	Excluded due to an incorrect population
Karkkonen 2001 ⁷⁴	Excluded due to an incorrect study design
Karlsson 1996 ⁷⁵	Excluded due to an incorrect outcome
Kersten 1995 ⁷⁶	Excluded due to an incorrect study design
Kilic Muftuoglu 2016 ⁷⁷	Excluded due to an incorrect study design
Klempner 2013 ⁷⁹	Excluded due to an incorrect study design
Korenberg 1996 ⁸¹	Excluded due to an incorrect intervention
Kowalski 2010 ⁸³	Excluded due to an incorrect outcome
Kowalski 2011 ⁸²	Excluded due to an incorrect study design
Krbkova 1996 ⁸⁴	Excluded due to an incorrect comparison
Kuhn 2012 ⁸⁶	Excluded due to an incorrect study design
Laasila 2003 ⁸⁷	Excluded due to an incorrect population
Lantos 2013 ⁸⁸	Excluded due to an incorrect study design
Lauhio 1994 ⁸⁹	Excluded due to an incorrect population
Lauhio 1991 ⁹⁰	Excluded due to an incorrect population
Lempner 2002 ⁷⁸	Excluded due to an incorrect study design
Liegner 1992 ⁹¹	Excluded due to an incorrect study design
Lipsker 2002 ⁹²	Excluded due to an incorrect study design
Ljostad 2008 ⁹³	Study abstract
Loewen 1999 ⁹⁴	Excluded due to an incorrect study design

Reference	Reason for exclusion
Loewen 2000 ⁹⁵	Excluded due to an incorrect study design
Luft 1988 ⁹⁷	Excluded due to an incorrect outcome
Luft 1989 ⁹⁶	Excluded due to an incorrect population
Maraspin 1995 ¹⁰³	Excluded due to an incorrect study design
Maraspin 1996 ⁹⁸	Excluded due to an incorrect study design
Maraspin 1999 ⁹⁹	Excluded due to an incorrect study design
Maraspin 2002 ¹⁰⁰	Excluded due to an incorrect study design
Maraspin 1999 ¹⁰¹	Excluded due to an incorrect study design
Maraspin 2002 ¹⁰²	Excluded due to an incorrect population
Marks 2016 ¹⁰⁴	Excluded due to an incorrect study design
McGill 1965 ¹⁰⁵	Excluded due to an incorrect population
Meyerhoff 2002 ¹⁰⁶	Excluded due to an incorrect study design
Meyerhoff 2016 ¹⁰⁷	Excluded due to an incorrect study design
Millner 1996 ¹⁰⁸	Excluded due to an incorrect outcome
Millner 1996 ¹⁰⁹	Excluded due to an incorrect outcome
Morales 2000 ¹¹⁰	Excluded due to an incorrect study design
Muellegger 1995 ¹¹²	Excluded due to an incorrect study design
Muellegger 1996 ¹¹¹	Excluded due to an incorrect comparison
Mullegger 1991 ¹¹³	Excluded due to an incorrect outcome
Nadelman 1993 ¹¹⁵	Excluded due to an incorrect study design
Nadelman 2001 ¹¹⁴	Excluded due to an incorrect population
Naglo 1989 ¹¹⁶	Excluded due to an incorrect study design
Neumann 1987 ¹¹⁹	Excluded due to an incorrect study design
Nimmrich 2014 ¹²¹	Excluded due to an incorrect study design
Nowakowski 2000 ¹²²	Excluded due to an incorrect study design
Nowakowski 1995 ¹²³	Excluded due to an incorrect study design
Ogrinc 2006 ¹²⁴	Excluded due to an incorrect population
Oksi 1999 ¹²⁵	Excluded due to an incorrect study design
Oksi 2007 ¹²⁶	Excluded due to an incorrect population
Oksi 1998 ¹²⁷	Excluded due to an incorrect population
Peltomaa 1998 ¹²⁸	Excluded due to an incorrect comparison
Pena 1999 ¹²⁹	Excluded due to an incorrect study design
Perronne 2015 ¹³⁰	Not available
Pfister 1988 ¹³¹	Excluded due to an incorrect outcome
Pirila 1951 ¹³⁴	Excluded due to an incorrect study design
Plorer 1993 ¹³⁵	Excluded due to an incorrect study design
Plotkin 1991 ¹³⁶	Excluded due to an incorrect study design
Puchalska 1996 ¹³⁷	Excluded due to an incorrect study design
Puri 2015 ¹³⁸	Excluded due to an incorrect comparison
Puri 2015 ¹³⁹	Excluded due to an incorrect study design
Rebman 2015 ¹⁴⁰	Excluded due to an incorrect study design
Renaud 2004 ¹⁴¹	Excluded due to an incorrect study design
Rohacova 1996 ¹⁴²	Excluded due to an incorrect comparison
Rose 1994 ¹⁴³	Excluded due to an incorrect study design
Rose 1996 ¹⁴⁴	Excluded due to an incorrect intervention

Reference	Reason for exclusion
Rubin 1992 ¹⁴⁵	Excluded due to an incorrect study design
Salazar 2005 ¹⁴⁶	Excluded due to an incorrect intervention
Salazar 1993 ¹⁴⁷	Excluded due to an incorrect study design
Sanchez 2016 ¹⁴⁸	Excluded due to an incorrect study design
Sandstrom 1989 ¹⁴⁹	Excluded due to an incorrect study design
Schmidt 1995 ¹⁵⁰	Excluded due to an incorrect study design
Selby 2008 ¹⁵¹	Excluded due to an incorrect study design
Shadick 1994 ¹⁵²	Excluded due to an incorrect study design
Shadick 1999 ¹⁵³	Excluded due to an incorrect study design
Shemenski 2016 ¹⁵⁴	Excluded due to an incorrect study design
Shoemaker 2006 ¹⁵⁵	Excluded due to an incorrect intervention
Sjowall 2012 ¹⁵⁷	Excluded due to an incorrect intervention
Sjowall 2011 ¹⁵⁶	Excluded due to an incorrect study design
Skogman 2003 ¹⁵⁹	Excluded due to an incorrect intervention
Skogman 2008 ¹⁵⁸	Excluded due to an incorrect study design
Skoldenberg 1988 ¹⁶⁰	Excluded due to an incorrect study design
Smith 2002 ¹⁶¹	Excluded due to an incorrect study design
Solomon 1998 ¹⁶²	Excluded due to an incorrect intervention
Spathling 1992 ¹⁶³	Article not in English
Stanek 1999 ¹⁶⁴	Excluded due to an incorrect study design
Steere 1980 ¹⁶⁸	Excluded due to an incorrect study design
Steere 1983 ¹⁶⁹	Excluded due to an incorrect study design
Steere 1987 ¹⁶⁵	Excluded due to an incorrect study design
Steurer 2016 ¹⁷⁰	Article not in English
Stricker 2011 ¹⁷¹	Excluded due to an incorrect study design
Stricker 2010 ¹⁷²	Excluded due to an incorrect study design
Strle 1996 ¹⁷³	Excluded due to an incorrect outcome
Strle 1996 ¹⁷⁴	Excluded due to an incorrect outcome
Strle 1992 ¹⁷⁵	Excluded due to an incorrect study design
Strle 1993 ¹⁷⁶	Excluded due to an incorrect outcome
Stupica 2015 ¹⁷⁸	Excluded due to an incorrect comparison
Stupica 2011 ¹⁷⁷	Excluded due to an incorrect comparison
Suarez-Magdalena 2017 ¹⁷⁹	Not available
Thompson 2012 ¹⁸⁰	Excluded due to an incorrect study design
Thorstrand 2002 ¹⁸¹	Excluded due to an incorrect study design
Thyresson 1949 ¹⁸²	Excluded due to an incorrect study design
Torbahn 2016 ¹⁸³	Excluded due to an incorrect study design
Tory 2010 ¹⁸⁴	Excluded due to an incorrect comparison
Tseng 2017 ¹⁸⁵	Excluded due to an incorrect outcome
Valesova 1996 ¹⁸⁶	Excluded due to an incorrect comparison
Vazquez 2003 ¹⁸⁸	Excluded due to an incorrect study design
Vazquez-Lopez 2016 ¹⁸⁷	Excluded due to an incorrect study design
Wahlberg 1994 ¹⁸⁹	Excluded due to an incorrect intervention
Weber 1988 ¹⁹¹	Excluded due to an incorrect study design
Weber 1987 ¹⁹⁰	Excluded due to an incorrect population

Reference	Reason for exclusion
Weissenbacher 2005 ¹⁹²	Excluded due to an incorrect intervention
White 2013 ¹⁹³	Excluded due to an incorrect study design
Zochling 1996 ¹⁹⁴	Excluded due to an incorrect study design

1 I.2 Excluded health economic studies

2 Table 20: Studies excluded from the health economic review

Reference	Reason for exclusion
None	None

3